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Abstract 
This project has been developed in the breakthrough framework of the Value Based Health 
Care (VBHC), which aims at improving health outcomes at lower cost in different medical 
conditions. The VBHC paradigm has been applied in cancer care to improve the 
management of the disease, considering epidemiological, medical, psychological and 
economic outcomes. 
Two studies have been designed and implemented to better investigate the psychological 
perspective of lung and prostate cancer patients, in the light of the VBHC paradigm.  
The project identifies the trend of clinical and psychological status over time and predict this 
change with sociodemographic or medical variables. Several categories of patients 
characterized by different trends were identified, elucidating the psychological dimension of 
cancer patients.  
A person-oriented approach was used to analyze patients’ recovery. One-year Quality of 
Life (QoL) trends in early stage of lung and prostate cancer patients undergoing surgery were 
identified. Patients’ recovery after surgery was characterized by both an overall decrease of 
symptoms and an increase of health and functioning over time.  
Prostate cancer patients showed different longitudinal trajectories of urinary incontinence 
and sexual dysfunction. In lung cancer patients, pre-surgery QoL, type of surgery, 
perioperative complications, and age, affected the post-surgery QoL as well as the linear and 
quadratic trends over time. 
Through the implementation of this holistic approach, the predictive model of patients’ 
recovery will be developed, thus improving medical decision-making, the choice of 
treatment, and patients’ awareness about their care process. Potential harms, QoL, and 
expected outcomes will be more predictable and better manageable. Participants will be 
more empowered, being more aware of their post-surgical care. 
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1. Introduction 
1.1 The meaning of value in health care  
The concept of value is a prominent topical issue in health care. Individual needs, 
preferences, and ethics affected the meaning of value, which in turn has been influenced by 
different cultures or historical periods [1]. The necessity of finding better ways of redirecting 
the incentives away from volume and toward value has led patients, physicians, policy 
makers, and other stakeholders to focus their attention on the meaning of value and its main 
features [2]. Even if a unanimous consensus on value’s definition has not yet been achieved, 
it is commonly accepted that values in health care may be defined as normative guidelines 
to evaluate actions or conditions and to influence the decision-making process [3–5]. 
Reputable organizations and associations based their definitions of value on expert judgment 
and empirical studies correlating value’s characteristics with measurable outcomes. The 
American Heart Association (AHA) underlines that, even though clinical efficacy and 
outcomes constitute the primary basis of good medical practice, value plays – together with 
costs – an important role including positive results in patient’s outcome, safety, and 
satisfaction [6].  
Different studies pointed out that the value’s definition changed with the reference sample: 
doctors’ values, most of the time, do not match the values of the patients, and vice versa 
[3,6,7]. In 2008, the Institute of Medicine (IOM) held a 2-day workshop to explore key 
stakeholders’ perspectives on the value in health care, seeking to understand the meaning of 
value [7]. Patients, providers, economists, payers, and employers, claimed that a mutually 
acceptable agreement among different points of views was difficult to be reached. Providers 
considered value on the appropriateness of care and on the effectiveness of evidence-based 
interventions, while economic representatives defined value as the clinical benefit achieved 
for the money spent. Patients, however, focused their attention on the ability of health care 
to satisfy their goals: a valuable intervention is a way of treating that also fulfills their needs 
[8]. Patient’s needs are frequently measured taking into account different aspects related to 
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Quality of Life (QoL), such as pain, emotional and cognitive functioning, or functional 
impairment [9,10]. Moreover, a recent review [11] on patient’s perceptions of quality of care 
emphasizes how communication, healthcare access, and shared decision-making are the key 
elements in a valuable healthcare environment. 
The absence of a common and widely accepted meaning of value allows each movement in 
healthcare practice to take into account different components of value. Over the last 10 years, 
the value was the key theoretical concept of different healthcare paradigms, leading to birth 
of different models of care.  
1.2 The Value-Based Health Care (VBHC): an in-depth explanation of the paradigm  
Between 2006 and 2013 at the Institute for Strategy and Competitiveness, based at the 
Harvard Business School, M.L. Porter and E. Teisberg (2006) developed and proposed a 
new health care model based on value, “a breakthrough framework for redefining healthcare 
competition based on patient value”[12]. 
A Value-Based Health Care (VBHC) should refer to three important principles [13]. Firstly, 
the proper goal for every stakeholder should be better health for their patients, not more 
treatments. Improving access to poor care or containing costs should be replaced with the 
overarching goal of enhancing patients’ value, defined as the best “health outcomes achieved 
per dollar spent” [14]. The health outcomes refer to the patient’s outcomes achieved over 
the full care cycle, the actual results of the care in terms of how well the patient actually 
does. Costs are the total costs of care for the patient’s condition, the actual cost of providing 
care and the resources involved in delivering care. Therefore, increasing value for patients 
means increasing quality, that is improving health outcomes without escalating costs or 
lowering costs without compromising outcomes[15]. Secondly, treatment delivery should be 
based on medical conditions and on the course of treatment a patient has to undergo. Each 
stakeholder plays a prominent role in determining the appropriate patient’s care pathway and 
the overall result derives from the quality of the total set of services provided. Lastly, 
outcomes should be measurable and recorded[13,16]. Data must be collected along the entire 
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patient cycle of care because the outcomes achieved are more effective measures than the 
number of services delivered - that would not be possible to previously know if they were 
properly and successfully used. Moreover, the outcomes should be interpreted on the basis 
of the costs effectively delivered across the full care cycle: cost reduction without 
considering outcomes would be dangerous and self-defeating[13].  
1.2.1 The Value Agenda 
These principles are the basis for a value transformation grounded on patients’ needs, health 
outcomes achieved, and costs collected in health-delivery organizations that follow the full 
care cycle of specific medical conditions. Porter and colleagues (2006) defined this strategy 
the “Value Agenda”[12,15].  
This strategic agenda has six interdependent and mutually reinforcing components: if they 
were advanced together, the implementation of a new model of health delivery would be 
easiest and fastest (see Fig.1).  
 
Figure 1: The Value Agenda. The model has been taken by Porter and Lee (2013) 
This model replaces the fragmented health care system with the introduction of Integrated 
Practice Units (IPUs) where each medical condition or set of related conditions are dealt by 
a multidisciplinary team of clinical and nonclinical providers trained to provide both patient 
and inpatient care. The current system is organized around the services provided, around the 
doctors, the tools. This agenda focuses on organizing care around the patient’s problem and 
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needs. Each medical condition is an interrelated set of patient medical circumstances and 
possible complications that frequently co-occur and involve multiple specialties and services 
(patient education, engagement, and follow-up). Uncoordinated, sequential visits to multiple 
providers and different departments would be converted into integrated and high-quality care 
within the same organization. The IPUs do not only refer to a clinical condition but also 
include programs for patient education, engagement, and follow-ups. Physical health IPUs 
should include dedicated mental health providers who understand the mental health needs of 
the patients they treat, detect developing mental illness, and intervene early. Incorporating 
mental health clinicians into primary care will improve patient value. Outpatient, inpatient, 
and rehabilitative care, as well as supporting services (e.g. nutrition, social work, behavioral 
health), would be encompassed in the full cycle of care[15].  
Health outcomes and costs for every patient should be recorded continuously in line with the 
care. Outcomes should cover the full cycle of care for the condition and track the patient’s 
health status after care is completed. The measured outcomes can be arrayed in a three-tiered 
hierarchy: health status achieved, the process of recovery, and sustainability of health (see 
Fig.2). Each tier includes two broad levels with various outcomes dimensions of patient’s 
health, each of them measured at different timing by several metrics. The patient health status 
(Tier 1) includes survival (or mortality) and the recovery achieved (clinical and functional 
status). The process of recovery (Tier 2) is composed of time required to achieve recovery 
over the care cycle (e.g. a phase of diagnosis, treatments, follow-up) and the disutility of the 
care process. This last dimension includes missed diagnosis, failed treatment, discomfort, 
ability to work or function normally while undergoing treatment, short-term complications, 
retreatment, and errors, together with their consequences. Lastly, Tier 3 includes the 
sustainability of health outcomes achieved referring to the degree of health maintained, 
possible disease recurrences and long-term complications, or to new health problems related 
to the previous treatments[17]. The selection of the outcome’s measures should be 
determined on each medical condition and patient’s initial status, sometimes also termed risk 
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factor for its probability to adjust patients’ recovery. A different set of outcomes are defined 
and combined all together accordingly to specific diseases: patient initial indicators (such as 
type of disease, age,…), acute care outcomes, complications or co-occurring conditions form 
the overall result of the full cycle of care. To define which type of measures should be 
appropriate for a specific disease, providers should understand the most relevant health 
circumstances and the set of services affecting patient’s results, the near- and long-term 
consequences of care, and the risk factors that may adjust the patient’s condition[17].  
 
Figure 2: The Outcomes Measures Hierarchy. The schema has been taken by Porter 2010, What is value in health care 
Moreover, stakeholders have to record the total of expenses in treating the full medical 
condition: the resources implied in patient’s care should be combined with the cost of 
supplying each of them, such as the personnel, instruments, and administration facilities.  
The third point of this overarching strategy for a value transformation includes a new type 
of payment approach: a value-based health care system should adopt a bundled payment to 
cover the full cycle of care for each type of disease (acute, chronic or preventive condition), 
a whole bundle of services required to deal with the patient’s medical problem. The bundled 
payment refers to the entire episode of care: a lump sum for the continuum of care associated 
with a specific medical condition is taken to a provider group, instead of paying separately 
for each performance provided (fee-for-service payment). In this type of payment, providers 
should primarily think about the entire patient experience among all care settings and 
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between episodic visits, and then convey them in a total cost of care encompassing all 
spending for the patient (see Fig. 3)[18].  
 
Figure 3: The Bundled Payment. The figure has been taken by Value-Based Care, Bundled Payments, & Direct 
Contracting, Shearwater Health, 2019. 
Therefore, bundled payment means setting a single price for each medical condition, 
including all visits and exams required for good care. It is not the cost of individual service, 
but the total cost of all the services required to deal with a specific medical problem. To 
maximize value for the patient, a bundled payment should 1) cover the entire care cycle 
required to treat a condition, 2) mandatorily report outcomes, such as returning to normal 
function, reducing pain or complications, 3) be adjusted for risk (e.g. sociodemographic 
characteristics or living conditions) that may affect patient’s health condition, 4) provide a 
fair profit by adding a margin over the full costs for an effective care, and 5) include a “stop-
loss” provision to limit providers’ exposure to unusually high costs from catastrophic or 
outlier cases.  
The fourth point of the Value Agenda is to integrate care delivery across separate facilities 
in order to eliminate the fragmentation and duplication of care. To optimize the types of care 
delivered in each location, an integrated care delivery system requires the definition of the 
aim of services provided and the concentration of volume of similar treatments in fewer 
locations according to the medical condition and its acuity level, the costs and intensity of 
resources and the need for convenience[15]. 
This integration would be further achieved by the application of the fifth step of this strategic 
agenda: the expansion of services across locations. Health care delivery systems should 
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extend their reach through the strategic expansion of excellent IPUs following a hub-and-
spoke or a clinical affiliation model. A hub-and-spoke model implies the presence of both a 
single IPU (hub) giving initial clinical consultations and establishing new treatment plans, 
and different satellite facilities (spokes) delivering less complicated - but more cost-effective 
- care. In most of the cases, fixed staff members are supported by several clinicians who 
rotate among locations. On the other hand, the clinical affiliation model is based on the 
affiliation of each IPU with community providers: leading providers use rural and 
community hospitals partners to deliver care rather than adding capacity to the single IPU. 
Through these models, both IPUs and local facilities will increase their value: the former 
could broad its regional reach, share management fees, revenue, or complex cases; while 
community providers could benefit from the expertise, experience, and reputation of the 
parent IPU and often improve their market. 
To implement all these steps, it is crucial to have an Information Technology platform able 
to help providers in integrating care across the care cycle, to better connect different facilities 
and IPU across geography or patients to the process. This platform should be patient-
centered, with an understandable and standardized terminology, and all data (e.g. physician 
notes, images, chemotherapy orders, lab tests) stored in a unique virtual place accessible to 
all parties involved in the patient’s health care. To respect these characteristics, the system 
should be designed in a simple way to extract information, including templates and expert 
systems for each medical condition[15]. 
These interrelated and organizational imperatives drive the health care system towards a 
paradigmatic shift from a volume-based to value-based care. The Value Agenda is set up to 
organize care around what patients need and to move away from a health care system based 
on what physicians do towards a patient-centered system.  
1.3 Applying the Value-Based Health Care system  
The aging population and increasing incidence of chronic diseases, innovative technologies, 
and new powerful drugs, led to a cost increase. The best way to reduce expenses is to define 
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and measure the health outcomes around the medical condition and improve them in order 
to add value to the healthcare path. Therefore, the aim of the VBHC model is to improve 
health outcomes at lower cost in different medical condition, from preventive to chronic 
situations. The organization, management, and measurement of outcomes and process of 
clinical care cycles constitute the core elements for a value transformation in hospitals and 
facilities. Along with process measurement, the outcomes should include performance-
improvement goals of providers and patients’ indicators of high-quality care[17,19]. The 
attention toward the health care system shifts from a volume of activity approach to a value-
based system, focused on results concretely obtained: doctors and hospitals would be paid 
based on outcomes achieved, not on numbers of procedures done, patients treated, or how 
much they were charged[14]. Moreover, rather than charging a patient for each individual 
test or service, payments would be bundled, supporting cost-effective care delivery while 
still being compliant with evidence-based guidelines. Primary care units should be replaced 
by care delivery processes based on subgroups of patients with similar needs, focusing on 
similarities in the type of care required and not on discrete diseases type such as diabetes, 
hypertension, or depression[20]. Electronic medical records for each patient would eliminate 
repetitive and unnecessary tests and procedures. To treat patients in a more efficiently and 
less time-consuming way, healthcare practitioners would communicate through the help of 
care coordinators. Patients would move through this integrated system more quickly and 
ideally would have fewer readmissions and less frequent hospitalizations or trips to the 
emergency room[20,21]. 
Changing the healthcare system is a long challenge partially carried out with the 
implementation of some of the concepts described above within the value-based framework. 
Nevertheless, the alignment of countries’ current health systems to key components of the 
VBHC model is still in progress. In 2016, the Economist Intelligence Unit (EIU) conducted 
a study on the adoption of value-based healthcare principles in 25 countries all over the 
World: 17 qualitative indicators, grouped into four domains, were identified to describe 
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different aspects of the VBHC model [22]. “Enabling context for value in healthcare”, 
“Measuring outcomes and costs”, “Integrated and patient-focused care”, and “Outcome-
based payment approach” were the identified four areas to display the level (from “Low” to 
“Very high”) of each country’s alignment with the value-based healthcare concepts. The 
United States, UK, and Sweden obtained the best scores, followed by Canada, France, and 
Australia. In fact, these countries were scored from “Very High” to “Moderate” in all the 
proposed domains. Germany and Japan showed “Low” scores only in the “Integrated and 
patient-focused care” and in “Outcome-based payment approach” area, respectively. The 
remaining nations were scored with “Low” in more than one area. Italy was not included in 
the study [22].  
The diversity among healthcare systems worldwide may lead to different time to implement 
the VBHC principles among countries, while differences in organizational processes and 
disease types may lead hospitals of each country to face great challenges in shifting towards 
value-based models.  
1.3.1 The VBHC system in Europe 
Globally, healthcare systems are plagued by a combination of rising costs, reduced access to 
good medical care, and a lack of transparency and coordination in assisting the delivery of 
effective treatment. Porter and Teisberg argue that the value was not based on enhancing 
long-term patient outcomes, but on short-term cost-saving cycles which focused on the 
clinical absence of disease[12]. Lack of standardization in measuring enhanced long-term 
patient outcomes has contributed to limited transparency in comparative treatment 
performance and the spread of non-evidence-based treatment-related information and 
practices[12]. The health care systems in Europe are still based on a supply-driven model 
rather than a patient-centered model, focusing on cost-containment rather than on patients’ 
value[23].        
Several European countries have been trying to implement the VBHC paradigm in 
accordance with the healthcare systems. Nevertheless, the lack of consensus about what 
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performance indicators should be used, who to reward and how to quantify the value of 
incentives to motivate further efficiency, has slowed down the adoption of VBHC and 
reduced the collection of cost and outcomes in the area of ambulatory and primary-care-
based interventions. Up to now, Germany, Spain, France, Portugal, UK, and Italy have been 
trying to apply some aspects of the paradigm[24]. Below a brief overview of these countries’ 
attempts to implement the VBHC paradigm in their healthcare systems. 
Germany focused on improving the process of delivering care, rather than on measuring 
patient outcomes and experiences. Increasing minimal volumes for procedures and creating 
centralized healthcare units (Integrated Practice Unit) specialized in specific diseases or 
procedures are the most common attempts to improve quality in Germany. Pay for 
performance and giving the regions greater power to take charge of healthcare policy are 
other implemented strategies to improve the healthcare system. In recent decades, data 
collection gained in importance: the Martini-Klinik became the leading hospital in showing 
that a better data collection focused on the patient experience may improve the overall 
outcomes[25]. The Cologne Care Research and Development Network (CoRe-Net) 
developed other three German projects based on the value-based framework. The Core-Net 
supported studies on patients’ and caregivers’ trajectories with heart disease and mental 
comorbidity, palliative care, and all organizations caring for the patient (inpatient and 
outpatient care, rehabilitation and private practitioners). Through a mixed-method design 
these research projects collected quantitative and qualitative data, analyzing medical, 
psychological variables and questionnaires on healthcare and statutory insurance funds[26–
28].  
In Spain, the continuous improvement in health technology assessment and the 
decentralization of the health administration enabled the sharing of best practices and the 
flexibility for innovation in regions. Using an online survey, the International Consortium 
for Health Outcomes Measurement (ICHOM) collected data on Spanish, Dutch and English 
patients with chronic kidney disease to establish a set of standardized health outcomes and 
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enable their measurement in routine clinical practice[29]. On the other hand, Parra and 
colleagues (2017)[30] applied the value-based paradigm at five hemodialysis centers, 
collecting clinical and economic outcomes. The obtained results helped stakeholders and 
policy makers in creating better context for healthcare and decision-making improvement.  
France and Portugal focused on the building of new Health Technology Assessment (HTA) 
and the implementation of primary healthcare and integrated care delivery, but both 
healthcare systems are still in progress. In Portugal, the high impact on the budget of some 
medical diseases, such as obesity, chronic renal disease, and pulmonary hypertension, has 
led to a faster implementation of integrated disease management programs and the 
development of coordinated medical and nursing services in hospitals, primary healthcare, 
and long-term care. On the other hand, France has also introduced new cost-effectiveness 
measures and financial incentives to encourage the creation of multi-disciplinary teams and 
the use of bundled payment systems[31,32].  
England has implemented more “value-based” changes in its healthcare system than other 
European countries. The National Health Service (NHS) is different from its “European 
neighbours”: it is more centralized, is funded by general taxation, including national 
insurance contributions, and is both publicly financed and operated primarily through the 
public sector, although market reforms have steadily introduced private providers within 
England over the last few decades. It has already adopted pay-for-performance models and 
has expertise in technology assessment for more than a decade[33]. The Quality and 
Outcomes Framework, the Best Practice Tariffs, and the Commissioning for Quality and 
Innovation are different English pay-for-performance programs providing financial 
incentives for primary or secondary care of chronic diseases[34]. Even if no single health 
system has yet to realize all aspects of the value agenda, England endorsed the concept of 
value as outcomes per cost, the adoption of IPU and the integration of primary and secondary 
care across the whole patient pathway to deliver value[35].  
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The Italian healthcare system is decentralized at both national and regional level: the 
significant degree of regional autonomy may lead to a lack of consistency and transparency 
in the provided healthcare services or a responsibilities’ overlap. The subsequent problems 
of miscommunication between the centers and the regions may get to a potential waste of 
efforts and costs. On the other hand, the development of a health technology assessment 
(HTA) infrastructure to collect, analyze and share data has been a slower process[36]. In 
2006, the Italian Health Technology Assessment Network (SIHTA) was founded to include 
all the separate HTA units among academic medical centers, research hospitals, and regional 
and local health authorities. Nevertheless, the multi-level structure of HTA in Italy has not 
yet provided full co-ordination and harmonization of practices and outcomes across the 
country. Moreover, just five out of Italy’s 21 regions and autonomous Provinces - Veneto, 
Emilia-Romagna, Lombardy, Piedmont, and Tuscany – have established structures to 
include HTA in their healthcare decision-making process. Nevertheless, there is a significant 
degree of variation in the way these regions have developed HTA. Many single bodies play 
a role in HTA decision-making in Veneto, for example, while the other four regions have a 
more centralized structure for carrying out the evaluation process. The industry is involved 
in the process only in Emilia-Romagna, while patient involvement occurs only in Piedmont; 
the other three regions provide no role for either industry or patients[37]. Many of the regions 
with the most developed HTA systems are also better organized and more efficient, with the 
result that they attract patients from other regions as well. Regional programs are nonetheless 
frequently constrained by a lack of sufficient data, which undermines transparency[36]. 
Along with the individual attempts to implement some aspects of the VBHC paradigm in 
each European country, in 2009, in Netherlands, a groups of academic and healthcare 
professionals founded the Value-Based Health Care Center Europe which brings national 
and international experiences together, and is right on top of the implementation of Value-
Based Health Care[38]. This European Network aims to facilitate the implementation of the 
concepts of VBHC, by developing new and existing methodologies, creating best practices, 
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and disseminating these among the international network. According to these principles, 
from 2014 this organization made up the VBHC Prize in order to recognize inspiring 
initiatives that focus on patients, engage patients and their families while delivering excellent 
patient value[38]. 
1.3.2 The VBHC system in cancer care 
Nowadays, the VBHC delivery initiative has been adopted in medical acute conditions or in 
chronic and primary care. The former includes joint replacements, different type of cancer, 
cardiological and neurological diseases, urological and gynecological procedures, and the 
observations room patients after Emergency Department care. On the other hand, primary 
care and chronic conditions focused on diabetes, heart failure, dementia, degenerative 
neurological diseases, and psychiatric disorders[39]. Several American and European 
hospitals, following the VBHC paradigm, have implemented some of its components, while 
others are still in development. In fact, care delivery is frequently fragmented, requiring 
multiple departments and disconnected providers to organize patient’s process of care. 
Implementing dedicated facilities staffed by dedicated teams and integrating different 
clinical interventions for a specific disease in a single care pathway may provide better care 
to patients and reduce the recovery burden, positively affecting the other measured 
outcomes[16]. 
As reported by the World Health Organization Report (2016), cancer causes the second 
greatest burden on patients across the European Union[40]. Today, the global cancer burden 
has risen to 18.1 million cases and 9.6 million cancer deaths [41], compared to five years 
ago, when the Global Cancer Statistics (GLOBOCAN, 2012) stated: “an estimated 14.1 
million new cancer cases and 8.2 million cancer deaths occurred in 2012 worldwide”[42]. 
In 2018, the European Union carries a significant load of the global cancer burden with 
almost one-quarter of the estimated cancer cases occurring in this area[41]. Following 
Porter’s idea, Johansen and Saunders (2017)[43] analyzed the healthcare organizations 
adopting the VBHC paradigm. Starting from these observations, they developed some 
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guidelines to apply the theoretical paradigm in cancer care. The four main steps to transition 
current cancer care into a value-based system are 1) defined for each type of cancer universal 
Patient-Reported Outcomes (PROs) over the full care cycle, 2) constitute multidisciplinary 
cancer-specific units, 3) establish a system capturing all data provided, and 4) continually 
improve treatment strategies through research. Thus, the VBHC has been applied to analyze 
specific cancer types and improve the management, combining epidemiological, medical, 
psychological and economical outcomes. Mapping the entire care cycle for a specific disease 
allows the stakeholders to identify all relevant outcomes and their measurement[14]. Fig. 4 
shows the value chain of care delivery in breast cancer. 
 
Figure 4: The Care Delivery Value Chain in breast cancer. The table has been taken by Porter 2010, What is value in health 
care. 
Therefore, the outcomes measures hierarchy in breast cancer implicates the collection of 
specific data for each tier. As suggested by Porter and colleagues, Tier 1 (survival and degree 
of recovery) includes survival rate, degree of remission, functional status, breast 
conservation, and depression. Tier 2 (time to recovery and disutility of care) would focus on 
the time of remission and functional status, infections, nausea, suspension of therapy, failed 
therapies, limitation of motion, depression. Finally, Tier 3 (stability of recovery and long-
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term consequences) may measure cancer recurrence, sustainability of functional status, 
incidence of secondary cancers, brachial plexopathy, fertility/pregnancy complications, and 
premature osteoporosis. Moreover, risk factors and initial conditions should be considered 
to make a baseline risk adjustment and consider their influence on all levels of the outcome 
hierarchy. Risk factors for patients with breast cancer may be the stage of disease, type of 
cancer, receptor status (positive or negative), sites of metastases, previous treatments, age, 
menopausal status, general health, including co-morbidities, and psychological and social 
factors. A great number of American and European healthcare organizations started 
collecting clinical data, but none of them measured the entire outcome hierarchy for the 
medical conditions[14]. The Martini-Klinik, an important German hospital, measured cancer 
patients’ functional and oncological outcomes following surgery. Patients were invited to 
complete a questionnaire on their quality of life, urinary and sexual functioning at four 
different times: 1) prior to their surgery, 2) one week after surgery, 3) three months after 
surgery, and 4) one year after surgery[25]. In 2012, the International Consortium for Health 
Outcomes Measurement (ICHOM) started to create standard sets of outcomes for specific 
medical conditions. Nowadays, breast, prostate, colorectal, and lung cancers have specific 
lists of standardized outcomes, measurement tools, and time points and risk adjustment 
factors[44]. The outcome measurement provides better opportunities for understanding 
whether care is benefitting patients and which treatments are most effective for each medical 
condition. Moreover, these data may allow a greater understanding of expenditures and 
foster a cost review: seven Dutch hospitals (the Santeon Network) highlighted an increase 
of 74% in the rate of reoperation due to complications in breast cancer patients and a 
reduction of nearly 30% in unnecessary inpatient stays. This network implemented the value-
based healthcare concepts among three different cancer patient’s groups (breast, prostate and 
lung) following the subsequent steps: 1) introduce a multidisciplinary team to define 
measured outcomes, 2) acquire internally clinical knowledge to better manage the care cycle 
and validate new medical processes, 3) share externally the knowledge to accelerate 
23 
 
improvements, and 4) collaborate with patients and payers to move toward value-based 
contracting[45].  
Several web-based platforms and mobile information technologies have been implemented 
to collect PROs and define the trajectories of patients’ recovery. Different hospitals in the 
US developed PRO measurement programs: the Memorial Sloan Kettering Cancer Center 
and the Group Health Cooperative in Seattle adopted IT platforms to collect outcomes in 
routine outpatients cancer care[46,47]. In 2016, a German hospital established a digital 
system to measure the PROs of breast cancer patients by the Breast ICHOM dataset and 
collected over 2500 questionnaires of 541 subjects[48]. The scientific literature shows that 
the installation of eHealth systems would increase data collection, reduce data loss and 
minimize errors in the data entry process. Moreover, patients declared that they would felt 
more comfortable using electronic systems, in comparison to paper and pencil-based 
methods[43,49]. The measurement of both clinical and patient-oriented health outcomes 
would be easier if specialty-oriented departments became cancer-specific multidisciplinary 
practice units which provide the full care cycle, thus favouring the financial transition from 
a fee-for-service to a bundled-payment system[43,46]. Nowadays, the IPUs are frequently 
implemented in hospitals treating a specific disease. The American MD Anderson Cancer 
Center applied the value-based principles organizing and integrating care within various 
medical fields and adopting a bundled payment program which divided expenses into three 
episodes of care (pre-treatment, treatment, and post-treatment phases)[50,51]. The Erasmus 
MC’s implemented the value-based strategy on breast cancer patients: an IPU with a 
multidisciplinary team of stakeholders was created collected and analyzed outcomes by 
electronic health records[52]. 
Several attempts have been made to apply the VBHC paradigm in European and American 
organizations: different healthcare systems imply different possibilities to make some 
changes in the care process and, most of the times, great changes require several years to be 
adopted. At this moment, the VBHC offers a new way of managing the healthcare process 
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and a possibility to discriminate which patients’ group better benefit from an intervention, 
enhance patient empowerment, and ensure that limited resources are used for the greatest 
patient benefit[43]. 
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2. Empirical contribution 
2.1 The VBHC paradigm at the European Institute of Oncology 
According to different healthcare systems and national governments, some aspects of the 
VBHC paradigm have been implemented around Europe. 
A literature search was conducted on Pubmed, Web of Science, Cochrane Library, Medline 
Ovid, Embase and Scopus using various combinations of database-specific controlled 
vocabulary (subject headings), supplemented by keywords, title and abstract terms for the 
concepts and synonyms relating to Value-Based Health Care (VBHC) in Italy. The aim of 
this review was to investigate if some Italian hospitals have already applied the VBHC to 
medical practice. The search strategy was included in the Appendix 1. 
Accruing evidence obtained by literature investigation reported that only two healthcare 
hospitals - located in Lombardy and Veneto regions - are applying and implementing only 
some principles of the VBHC model. The Veneto Region, through the VBHC working 
group, is currently developing a pilot project in the field of cardiology and cardiac surgery, 
including in the study cohort patients who underwent transcatheter aortic valve implantation 
(TAVI)[53]. On the other hand, the European Institute of Oncology (IEO, Milan) has been 
collecting patient’s health outcomes and the related direct/indirect costs to increase health 
benefits and save costs.  
In 2015, IEO applied the VBHC model in different oncological divisions, starting the Value-
Based Medicine (VBM) project. Following Porter’s idea, the primary aim of the project was 
to build an equation that relates altogether clinical outcomes (efficacy and tolerability of 
treatment, complications) with direct and indirect costs incurred by the system. The result of 
this equation is the value, intended as a measure of different dimensions of health that 
represents the maximum health protection achieved for each euro spent. Therefore, the term 
"value" was not due to the "cost" of an intervention, but rather to the overall assessment of 
patient’s benefits and complications, integrating all these aspects in one macro - indicator.  
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The holistic approach of the VBHC paradigm implies the collection of economic, medical 
and psychological outcomes, that will contribute to design personalized predictive model of 
patient’s recovery after surgery. Through this predictive model of care, participants would 
be more empowered, receive a more complete framework of post-surgical care pathway, and 
improve their health literacy and decision-making.  
Starting from these premises, the project would analyze principal and interaction effects 
between outcomes and costs investigating the associations among psychological, medical 
and economic aspects of patient’s process of care, and studying if the psychological status 
may impact on costs, rehabilitation, and drug consumption or medical examinations. 
The study has been conducted on patients with prostate and lung cancer. The VBM project 
will be also conducted on breast cancer patients. 
Since the VBM project is a multidisciplinary study, several stakeholders have 
simultaneously carried out research studies investigating different aspects of the care 
process. Social workers and economists collected and analyzed economic outcomes, 
physicians and trained nurses focused on the medical condition over time, and psychologists 
investigated patient’s well-being. All the researchers followed the VBHC principles and 
shared their results to build a unified predictive and personalized model of care.  
Data were collected at different time points consistently with the patient’s recovery and 
follow ups. At pre-surgery (baseline), the project was personally explained to each subject 
and only after the informative consent they were enrolled in the study. The baseline 
recruitment was vis-à-vis, while the other time points of data collection were conducted by 
telephone or e-mail. Clinical and psychological information were extracted from medical 
records and standardized questionnaires, while social workers collected economic data 
following a search grid.  
2.2 Introduction to the research studies 
Within the VBM project, in collaboration with the Psychoncology Division, two pivotal 
researches have been designed and implemented on lung and prostate cancer patients. In 
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order to involve the psychological outcomes in the VBHC paradigm, the following aims 
have been developed:  
1. To identify the trend of clinical and psychological status over time and predict this 
change with sociodemographic or medical variables;  
2. To identify categories of patients characterized by a different trend of clinical and 
psychological status over time and assess differences in sociodemographic or 
medical variables among them; 
3. To further investigate the psychological dimension of cancer patients.  
The studies on prostate and lung cancer patients are already completed, while the Breast 
Cancer Unit has been starting the recruitment. Therefore, the obtained results on prostate 
and lung cancers will be here discussed. 
The VBHC paradigm theorizes QoL as the only psychological factor that may affect the 
patient’s value. For this reason, our studies on prostate and lung cancer patients focused on 
QoL measurement. Sub-chapters 2.3, 2.4, 2.5, and 2.6 will include the validation studies of 
the used QoL questionnaires and the predictive trajectories of patients’ recovery after 
surgery both from a clinical and psychological perspective. Since the included studies had 
different sample, statistical analyses and results, the Discussions will directly follow each 
Results section. The statistical analyses conducted on prostate cancer patients were able to 
satisfy both the first and the second of the primary aims. On the other hand, the sample of 
lung cancer patients was too small to identify categories of patients characterized by different 
trend of clinical and psychological status over time (second aim). Due to this statistical 
limitation, we only identify the overall trend of clinical and psychological status over time 
and predict this change with sociodemographic or medical variables.  
To sum up, paragraphs 2.3 (study 1a) and 2.4 (study 1b) will show the Italian validation of 
the questionnaire (the EPIC-26) used to measure QoL in prostate cancer patients and their 
trends over the care process, respectively. On the other hand, paragraphs 2.5 (study 2a) and 
2.6 (study 2b) will include the EORTC QLQ-C30 Italian validation (used to collect data on 
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QoL of lung cancer patients) and the identified trajectories of QoL subdimensions over one-
year after surgery. 
2.3 Study 1a: Validation of the Italian Version of the Abbreviated Expanded Prostate 
Cancer Index Composite (EPIC-26) in Men with Prostate Cancer 
A recent systematic review showed that, among the great availability of prostate-cancer 
specific questionnaires measuring PROs, the Expanded Prostate Cancer Index Composite 
(EPIC) is the most suitable cancer-specific survey in urology departments to measure 
patient’s physical and psychological well-being[54]. Through the “Evaluating Measures of 
Patient-Reported Outcomes” (EMPRO) tool, the EPIC obtained, along with the University 
of California Los Angeles-Prostate Cancer Index (UCLA-PCI), the highest score in terms of 
concepts and population intended to assess, and very high scores in validity, interpretability, 
and responsiveness. Moreover, EPIC was also recommended because it is the only 
questionnaire investigating hormonal and irritative/incontinence urinary dysfunction 
domains. The original version of EPIC is composed of 50 items and is developed by Wei 
and colleagues[55]. Considering the difficulty of administering the questionnaire during 
clinical practice, a short version was introduced composed of 26 items. The new version, 
named EPIC-26 (Appendix 2), is the most used brief self-report scale and it has already been 
validated in Norway, USA, China and Germany[56–59]. 
Its administration allows physical and psychological information to be collected on specific 
dimensions, as urinary incontinence, urinary irritation, bowel, sexual and hormonal 
dysfunction, scored from 0 (worst) to 4 or 5 (best). All domains of EPIC-26 are highly 
correlated with all domains of the longer version EPIC-50 (r ≥ 0.96)[56–59]. 
The proposed factor structure for the EPIC-26 is a correlated five-factor model (CFFM) 
[59,60]. As shown in Figure 5, urinary incontinence and urinary irritation are both measured 
by four items; bowel and sexual dysfunctions are both measured by six items, while five 
items measure hormonal dysfunction. A single item (i.e., item 9) measuring overall urinary 
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symptomatology is a stand-alone item and is not included in any of the domains because it 
overlaps on both urinary incontinence and urinary irritation. 
High internal consistency and test-retest reliability - Cronbach's alpha ≥ 0.70 and r ≥ 0.69 
respectively - have been reported in all the domains[59–61]. These psychometric properties, 
along with being less time-consuming and easier to use than the full version, encouraged the 
use of the EPIC-26 in clinical and research settings over time.  
Considering the pivotal role of the EPIC-26 to assess QoL in prostate cancer patients[54], 
the main aim of this study was to develop an Italian version of this self-report measure and 
to evaluate its psychometric properties in term of dimensionality, longitudinal invariance, 
and reliability in term of both internal consistency and test-retest reliability. 
 
Figure 5: The correlated five-factor model 
Note: IN = Urinary incontinence; IR = Urinary irritation; BD = Bowel dysfunction; SD = Sexual dysfunction; HD = 
Hormonal dysfunction. 
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2.3.1 Materials and method 
Participants and procedure 
An Italian sample of 284 patients with localized prostate cancer who had undergone Robot-
Assisted Radical Prostatectomy (RARP) was recruited at the European Institute of Oncology 
in Milan between July 2015 and July 2016. Patients were included in the study if they: 1) 
were diagnosed with localized prostate cancer, 2) were native Italian speakers, 3) referred to 
the Value-Based Project and 4) had neither neurological nor psychopathological problems. 
They completed the questionnaire 45 days (T1) and 6 months (T2) after RARP surgery. 
Informed consent was provided and signed by each participant. The participation in the study 
was voluntary and at each moment, patients could withdraw their consent. The study was 
developed in accordance with the principles stated in the Declaration of Helsinki (59th WMA 
General Assembly, Seoul, 2008) and was approved by the Ethical Committee of the 
European Institute of Oncology.  
Language equivalence 
Transcultural adaptation of the EPIC-26 survey in Italian was done using forward and 
backward translation by two experts[62]. One English native speaker translated the original 
English EPIC-26 version into Italian. Then, two expert psychologists assessed the 
consistency of the translation and approved the first version of the Italian EPIC-26. This 
version was pretested in a cognitive debriefing study with ten prostate cancer patients in 
order to assess its readability, understand ability, and comprehensibility. The cognitive 
debriefing was conducted by a psychologist. The time taken by each patient to complete the 
EPIC-26 was recorded. Patients then completed a cognitive debriefing task in which they 
asked about the clarity of the instructions and items, and the level of ease of response to each 
item.  
Instructions (M = 4.80, ds = 0.632) and items (M = 4.96, ds = 0.08) were rated as clear on a 
five-point Likert scale (ranging from 1 = not at all to 5 = completely). Items were also rated 
as easy to complete (M = 4.96, ds = 0.07) on a five-point Likert scale (from 1 = not at all to 
31 
 
5 = completely). Only two patients asked for further information about the “13.b” item 
(“breast tenderness/enlargement”): they did not understand the meaning of the question and 
asked for more information. They did not know this side effect and were not able to visualize 
it as a possible consequence of the disease. Then, a second mother tongue speaker translated 
this version back into the English language. The results of this back-translation were 
virtually identical to the original English version. 
Statistical Analysis 
 The psychometric properties were assessed using structural equation modeling in a sample 
of patients who had undergone Robot-Assisted Radical Prostatectomy (RARP). Specifically, 
we aimed at assessing the goodness of fit of the CFFM for the EPIC-26 using confirmatory 
factor analysis (CFA) and testing reliability. Then, longitudinal invariance was assessed to 
evaluate the ability of the EPIC-26 to reliably and validly measure its relevant constructs 
over time. Longitudinal invariance is a necessary requisite to assess stability and change of 
constructs over time since without invariance it is not possible to distinguish between true 
changes in outcomes over time and differences in the psychometric properties of the 
instrument.CFA with robust maximum likelihood (MLR)[63] was performed with Mplus 
8.2 to evaluate the CFFM of the EPIC-26 separately at T1 and T2. Overall goodness-of-fit 
of the proposed models was evaluated assessing multiple indices of fit: the chi-square test 
(Χ2), the root mean square error of approximation (RMSEA), the comparative fit index 
(CFI), the Tucker-Lewis index (TLI), and the standardized root mean square residual 
(SRMR). The model fit was firstly evaluated using the Χ2 statistic. However, because of its 
sensitivity to the sample size, other indices were also used[64]. Specifically, values above 
.90 for the CFI and TLI, a RMSEA below .06, and a SRMR below .08 indicate a good fitting 
model. The assessment of longitudinal invariance is a sequential process with seven specific 
steps. As reported in Table 1, configural, metric, scalar, and residual variances invariances 
were sequentially performed and followed by invariance of the latent factor variances, 
covariances, and means. The main assumption of configural invariance is that the same 
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factor structure will hold in the two waves. Metric and scalar invariance respectively assume 
that factor loadings and item intercepts are equivalent across time. The assumption of 
residual invariance is that the residual variances of items are equivalent across time. Equality 
of residual variances implies equal reliability over time. Finally, the invariance of factor 
variances, covariances, and means assume respectively that latent factor variances, 
invariances, and means are equal across the two waves. The difference in CFI (i.e., ΔCFI) 
between a model and the subsequent level of invariance was considered to evaluate whether 
the hypothesis of invariance should be retained. Measurement invariance is indicated by a 
ΔCFI less than or equal to -.010[65]. When invariance was not found, we tested partial 
invariance by checking modification index (MI). At each step, we identified all the non-
invariant parameters by reviewing MI and then freely estimated these parameters across 
time. Analyses were performed using the full-information maximum likelihood estimator, 
which allows for inclusion of cases with partially missing data. 
Table 1 – The sequential process to assess longitudinal invariance. 
Model Title Description 
A Configural model The factor structure is the same across waves 
B Metric model A + all factor loadings are constrained to be 
equivalent across waves 
C Scalar model B + all item intercepts are constrained to be 
equivalent across waves 
D Residual variances model C + all residual variances of items are 
constrained to be equivalent across waves 
E Factor variances model D + all latent factor variances are constrained to 
be equivalent across waves 
F Factor covariances model E + all covariances among latent factors are 
constrained to be equivalent across waves 
G Factor means model F + all latent factor means are constrained to be 
equivalent across waves 
 
Internal consistency was assessed by computing respectively Cronbach’s alpha of each 
dimension in the two waves.  Test-retest reliability was computed by considering intraclass 
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correlations (ICCs). Specifically, ICCs (and their 95% confidence interval) were used to 
examine correlations between repeated measurements of each QoL dimensions obtained 
from the same patient at different times (i.e., T1 and T2). We used ICC Model 3 (i.e., two-
way mixed effects, absolute agreement, single measure/rater) to quantify test-retest 
reliability[66,67]. ICC values below 0.50 were considered to indicate poor reliability, from 
0.50 to 0.75 moderate, from 0.75 to 0.90 good, and above 0.90 excellent reliability[68].  
2.3.2 Results 
As shown in Table 2, participants had a median age of 63.4 ± 7.12 and a BMI of 26.6 ± 3.54. 
Two hundred and thirty-three men underwent radical prostatectomy with nerve-sparing (NS) 
surgical procedure (N=159 with bilateral NS; N=75 with unilateral NS), while the other 
17.6% (50/284) of the sample undergone surgery without NS. The distribution of item 
responses was reported in Table 3. 
Table 2 - Sample characteristics 
 N 
Age 63.4 ± 7.12 
  
BMI 26.6 ± 3.54 
  
Type of surgery  
Bilateral NS 159 
Unilateral NS 75 
Without NS 50 
 
Table 3 – The distribution of item responses 
 T1 T2 
ITEMS M SD M SD 
1 2,13 1,59 3,72 1,62 
2 2,75 0,76 3,30 0,68 
3 1,41 1,08 0,46 0,73 
4a 1,92 1,26 0,90 1,07 
4b 0,62 0,94 0,10 0,38 
4c 0,20 0,58 0,01 0,13 
4d 0,79 1,09 0,40 0,77 
4e 1,90 1,21 1,08 1,14 
6a 0,42 0,79 0,28 0,63 
6b 0,34 0,72 0,21 0,59 
6c 0,03 0,19 0,03 0,26 
6d 0,02 0,12 0,03 0,19 
6e 0,75 1,00 0,28 0,62 
7 1,55 0,90 1,31 0,69 
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8a 1,58 0,94 1,82 1,08 
8b 1,87 1,19 2,28 1,27 
9 1,91 1,13 2,19 1,20 
10 1,91 1,33 2,15 1,36 
11 1,57 0,97 1,73 1,07 
12 2,81 1,39 3,02 1,46 
13a 1,12 0,47 1,25 0,73 
13b 1,08 0,38 1,10 0,40 
13c 1,56 0,91 1,56 0,99 
13d 1,90 1,08 1,54 0,94 
13e 1,38 0,78 1,34 0,80 
 
At T1, the CFFM model displayed a good fit to data [SB Χ2 (265) = 553.092, p = .000; 
RMSEA = .055; CFI = .921; TLI = .911; SRMR = .067]. Similarly, the model showed an 
adequate fit also at T2 [SB Χ2 (265) = 605.020, p = .000; RMSEA = .060; CFI = .907; TLI 
= .894; SRMR = .061]. Specifically, all standardized factor loadings except the ones for 
items 13 and 23 are significant at T1. At T2, all standardized factor loadings are significant 
except the ones for items 7, 12, and 13.  
Table 4 summarizes the sequential process of assessing measurement invariance by reporting 
fit indices of each model and the ΔCFI between them. In the first step, configural invariance 
was assessed. Specifically, fit indices attested that the CFFM had a good fit in both waves 
hold in the two waves [SB Χ2 (1105) = 1892.249, p = .000; RMSEA = .044; CFI = .913; 
TLI = .904; SRMR = .062]. Equivalence of the factor loading across waves was then 
examined in the metric invariance model. This model did not fit significantly worse than the 
configural model (ΔCFI = -.010) thus indicating that each item was related to the latent factor 
equivalently across waves. The scalar invariance model fitted significantly worse than the 
metric invariance one (ΔCFI = -.028). Subsequently, the MIs suggested that the intercept of 
items 14, 5, 25, 6 and 21 were the main sources of significant misfit and should be freely 
estimated across waves. After doing this, the partial scalar invariance model did not fit 
significantly worse than the metric invariance one (ΔCFI = -.009) and thus denoting that T1 
and T2 had the same expected response for each item except for items 14, 5, 25, 6, and 21 
at the same absolute level of the traits being measured. The residual variances invariance 
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model fitted significantly worse than the partial scalar one (ΔCFI = -.012). The MIs 
suggested that the residual variances of items 13 and 22 should be freely estimated across 
the two waves. After doing so, the partial residual variances invariance model did not 
significantly fit worse than the previous invariance model (ΔCFI = -.005) and thus denoting 
that the amount of item variance not accounted by the latent factor was the same across the 
two waves except for items 13 and 22. After reaching partial measurement invariance, 
structural invariance was assessed by evaluating factor variances, factor covariances, and 
factor means invariance. The factor variance model did not fit significantly worse than the 
partial residual variances invariance model (ΔCFI = -.002) thus indicating equivalent 
variances or namely equal amounts of individual differences in QoL across the two waves. 
Results demonstrated the equivalence of relationships among the five latent factors across 
waves as indicated by a no significant decrease of model fit between the factor covariances 
invariance model and the previous model (ΔCFI = -.004). Finally, the factor means 
invariance model fitted significantly worse than the factor covariances model (ΔCFI = -
.036). The MIs suggested that the means of the latent factors of urinary incontinence and 
urinary irritation should be freely estimated across the two waves. After doing so, the partial 
factor means invariance model did not significantly fit worse than the previous invariance 
model (ΔCFI = -.006) and thus denoting that only these two factors means were significantly 
different and decreasing over time.   
Table 4 – Results of the sequential process of assessing measurement invariance of the 
EPIC-26. 
Model SB Χ2 df p RMSEA CFI TLI SRMR ΔCFI 
Configural Invariance 1892.249 1105 .000 .044 .913 .904 .062 - 
Metric Invariance 2003.830 1125 .000 .047 .903 .895 .068 -.010 
Scalar Invariance 2279.990 1145 .000 .052 .875 .866 .071 -.028 
Partial Scalar Invariance - Item 14 2225.603 1144 .000 .051 .881 .872 .071 -.022 
Partial Scalar Invariance – Item 5 2196.445 1143 .000 .051 .884 .876 .070 -.019 
Partial Scalar Invariance – Item 25 2155.922 1142 .000 .050 .888 .880 .070 -.015 
Partial Scalar Invariance – Item 6 2126.187 1141 .000 .049 .891 .883 .069 -.012 
Partial Scalar Invariance – Item 21 2101.490 1140 .000 .048 .894 .886 .069 -.009 
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Residual Variance Invariance 2232.515 1160 .000 .051 .882 .875 .078 -.012 
Partial Residual Variance Invariance – Item 
13 
2219.857 1159 .000 .050 .883 .876 .075 -.011 
Partial Residual Variance Invariance – 
Item 22 
2167.399 1158 .000 .049 .889 .882 .072 -.005 
Factor Variance Invariance 2191.584 1163 .000 .050 .887 .881 .077 -.002 
Factor Covariance Invariance 2231.046 1173 .000 .050 .883 .878 .078 -.004 
Factor Mean Invariance 2562.749 1178 .000 .057 .847 .841 .098 -.036 
Partial Factor Mean Invariance – Urinary 
Incontinence 
2383.217 1177 .000 .053 .867 .862 .081 -.016 
Partial Factor Mean Invariance – Urinary 
Irritation 
2291.617 1176 .000 .051 .877 .872 .078 -.006 
Note: SB = Satorra-Bentler Chi Square; df = degree of freedom; RMSEA = Root mean 
square error of approximation; CFI = Comparative fit index; TLI = Tucker-Lewis index 
(TLI); SRMR = Standardized root mean square residual; ΔCFI = Difference in CFI between 
models.   
 
This final model showed an adequate fit to data [SB Χ2 (1176) = 2291.617, p = .000; RMSEA 
= .051; CFI = .877; TLI = .872; SRMR = .078]. Standardized parameters of this model are 
reported in Figure 6. All the standardized factor loadings are significant and above .30 in 
absolute value with the exception of items 5, 6, 12, 13, 22, and 23. Intercepts of items 5, 6, 
14, and 25 decreased across waves while the intercept of item 21 increase from T1 to T2. 
Regarding residual variances, all non-equivalent items showed a decrease of residual 
variance except for items 13 and 22 that showed an increase of residual variance over time. 
All the factor variances and covariances are equivalent across time attesting the structural 
stability of the EPIC-26 questionnaire. Factor correlation ranged between .187 and .622 in 
absolute value with the highest link between urinary incontinence and urinary irritation. 
Finally, three-factor means (i.e., bowel, sexual, and hormonal dysfunctions) showed to be 
equivalent across waves; on the contrary, urinary incontinence and urinary irritation decrease 
from the first to the second wave.  
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Figure 6: Standardized parameters of the final CFFM. 
Note: IN = Urinary incontinence; IR = Urinary irritation; BD = Bowel dysfunction; SD = Sexual dysfunction; HD = 
Hormonal dysfunction. 
 
Results of the reliability analysis attested the good internal consistency and test-retest 
reliability of each dimension (Table 5). Specifically, all Cronbach’s alphas could be 
classified as minimally acceptable (i.e., above .65) except for low Cronbach’s alpha for 
hormonal dysfunction at T1 and urinary irritation at both waves. Urinary incontinence and 
sexual dysfunction display optimal reliability with values of Cronbach’s alpha above .80 in 
both waves. Finally, ICCs attested the good test-retest reliability of each dimension. 
Specifically, ICC for urinary incontinence could be classified as good, whereas the ICCs for 
the remaining dimensions could be considered as moderate. 
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Table 5 – Cronbach’s alphas and ICC assessing internal consistency and test-retest 
reliability of the EPIC-26. 
Dimension T1  
Cronbach’alpha 
T2 Cronbach’alpha ICC correlation 
(95% CI) 
Urinary 
incontinence 
.886 .862 .764 (.717-.804) 
Urinary irritation .585 .518 .600 (.529-.662) 
Bowel dysfunction .699 .736 .536 (.458-.606) 
Sexual dysfunction .860 .902 .552 (-.088-830) 
Hormonal 
dysfunction 
.638 .700 .636 (.570-693) 
 
2.3.3 Discussion 
This study represents the first attempt to assess the validity of the Italian version of the EPIC-
26. The factor structure, longitudinal invariance, and reliability of the Italian version of the 
EPIC-26 were investigated in a sample of Italian prostate cancer patients who had undergone 
RARP. Results of the CFA demonstrated that the proposed CFFM provided a good fit to 
data at both waves in these patients. These results support the usefulness and validity of 
computing separate scores for each of the five domains of urinary incontinence, urinary 
irritation, bowel dysfunction, sexual dysfunction, and hormonal dysfunction. The results of 
the reliability analyses attest the acceptable internal consistency and test-retest reliability of 
most of the EPIC-26 domains. The urinary irritation subscale is the only dimension showing 
a poor internal consistency with values of Cronbach’s alpha below the minimally acceptable 
cut-off at both waves. This result is consistent with previous empirical evidence regarding 
the weak reliability of this subscale in the Chinese version of the EPIC-26[58]. Following 
suggestions by Lam and colleagues[58], the low reliability of this subscale may be 
determined by the high proportion of patients reporting no problem on the first two items 
(pain on urination and bleeding with urination) of this domain and a higher proportion of 
patients reporting moderate problems or incomplete emptying and need to urinate frequently 
during the day. Another possible explanation of this low reliability is the limited number of 
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items in this domain compared with other domains (urinary incontinence, sexual, bowel, and 
hormonal dysfunction). Notably, the first two items measuring urinary irritation, alongside 
with item 2 (urinary control), item 13 (bloody stools), item 22 (hot flashes), and item 23 
(breast tenderness) display a low factor loading below .30. Thus, all these items could be 
considered weak indicators of their respective dimensions. Further research is needed to 
identify more reliable indicators of urinary irritation in patients with prostate cancer by 
developing new ad-hoc items. Regarding test-retest reliability, all dimensions displayed at 
least moderate reliability. 
Testing longitudinal measurement invariance is a pre-requisite for understanding whether 
changes in patients’ urinary incontinence, urinary irritation, bowel dysfunction, sexual 
symptomatology, and hormonal dysfunction over time reflect true changes in quality of life 
or rather changes in the psychometric properties or structure of the EPIC-26 over time. This 
study also demonstrated the good longitudinal invariance of the EPIC-26. This self-report 
measure was administered to the same sample of patients with prostate cancer who had 
undergone RARP in order to assess all the sequential steps of measurement invariance over 
time. Results demonstrated a full weak invariance of the EPIC-26 across time. Specifically, 
its entire factor loading is invariant over time and, thus, indicating that all of them are related 
to their respective domains equivalently across waves. We also demonstrated a partial strong 
invariance and a partial strict invariance of the EPIC-26 over time attesting respectively that 
the majority of the expected responses are equivalent over time and that the amount of item 
variance not accounted by the latent factor was the same across the two waves. The non-
invariant thresholds of items 5, 6, 14, 21, and 25 suggested that patients evaluate these 
specific symptoms differently over time. Specifically, responses to these items revealed that 
patients who had undergone RARP reported a significant decrease over time of pain or 
burning on urination, bleeding on urination, bloody stools, and lack of energy. Conversely, 
they showed a significant increase in amount of problem-related to their sexual function or 
the lack of sexual function. 
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Finally, after the partial strict invariance, results also attested the structural invariance of the 
EPIC-26 across the two waves. We found the equivalence of factor variances and 
covariances over time suggesting respectively that the same amounts of individual 
differences in patients’ quality of life were found between T1 and T2 and that strong 
structural stability exists among the five EPIC-26 domains over time. Moreover, the five 
EPIC-26 domains showed from moderate to strong stability across time. Finally, the results 
of the factor mean invariance demonstrated that the levels of bowel, sexual, and hormonal 
dysfunctions tend to be equal over time. On the other hand, self-reported levels of urinary 
incontinence and irritation significantly decreased from 45 days to 6 months after the RARP.  
A large number of studies using this instrument (the 50- and 26-item versions)[54] and the 
high number of language translations[56–59,69–74] make an Italian validation necessary. 
The Italian validation of the Expanded Prostate Cancer Index Composite – Short Form 
confirms its validity and reliability in measuring Quality of Life in prostate cancer patients 
over time. Beyond its reliability, the Short Form is easier than the longer version of the 
questionnaire, reducing administration burden with only 10 minutes for the compilation[54].  
Limitations 
One of the main limitations of this study is the lack of other self-report measures of quality 
of life or patients’ well-being, which could be useful to better assess convergent and/or 
divergent validity of the EPIC-26. However, we did not include any other measures to 
minimize the burden on such patients. 
Moreover, the EPIC-26 was administered to patients who had undergone RARP only; the 
lack of other treatment types may affect the internal consistency.  More precisely, our results 
may show poor internal consistency in the urinary irritation subscale because patients who 
had undergone RARP did not suffer from this side effect.  
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2.4 Study 1b: Predicting trajectories of recovery in prostate cancer patients 
undergone Robot-Assisted Radical Prostatectomy (RARP) 
Despite all advancements in surgical and radiant treatments, a recent study shows that 
regardless any treatments, 90% of PC survivors reported at least one physical impairment 
during the two-years post-diagnosis. Sexual, urinary and bowel dysfunctions are the most 
common functional consequences after PC treatments and they may persist for several 
years[75,76]. Compared to radiotherapy and active surveillance, men who underwent robot-
assisted radical prostatectomy (RARP) reported greater negative side effects especially in 
the first 6 months from the surgery, even though there was a partial recovery[77]. Sixty 
percent of men suffer from urinary incontinence and sexual problems after surgery, that are 
often related to distress and fatigue symptoms. Following a variable-oriented approach, 
several studies investigate the trend of these symptoms showing that patients live longer with 
these side effects that deeply affect their quality of life for months after treatment[78–82]. 
Nevertheless, it would be also important to identify different categories of PC patients with 
different trends in recovery over time through a person-oriented approach that can better 
display which kind of patients may have higher difficulties in the recovery of their functional 
and psychological abilities. The person-oriented approach is a valid alternative to the 
traditional variable-oriented methodology. The main analytic units of the variable-oriented 
approach in health research are individual behaviours, health-related variables or construct 
that may vary both within populations or over time[83]. In this kind of approach inter-
individual differences are rarely taken into account because they are considered random and 
negligible [84]. On the contrary, the main assumption of the person-oriented approach is that 
people are unique and that this uniqueness is measurable and worth knowing[85]. The main 
analytic units of this approach are individuals or homogeneous subpopulations. From this 
perspective, inter-individual differences are meaningful and may be especially helpful to 
classify individuals into distinct classes. Individuals belonging to the same class are similar 
to each other while they are quite different from those classified in other classes. Concerning 
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prostate cancer, Chambers et al. (2017)[86] applied a person-oriented approach to 
understand which factors can affect different trajectories of patients’ recovery in Quality of 
Life, life satisfaction and psychological adjustment after different prostate cancer treatments, 
but nobody has already focused the study research on physical function’s recovery in men 
with prostate cancer after RARP surgery.   
Clinical and sociodemographic characteristics may foreshadow the partial recovery of men 
treated with RARP. Different studies showed that age, body mass index (BMI), and diabetes 
may predict long-term post-operative incontinence after RARP[87,88]. While preservation 
of the neurovascular bundle, age, and pre-surgery sexual condition were considered as 
positive predictors of potency recovery following RARP[89–91]. Therefore, patients’ 
characteristics play an important role in months after surgery: some pre-intervention 
sociodemographic and clinical variables may influence and predict the typical trend of 
patient’s recovery after robot-assisted radical prostatectomy. 
Physical dysfunctions are normally present during the months after surgery, highly affecting 
patient’s survivorship and Quality of Life[79]. This new study perspective may help people 
involved in the care process to better identify possible trajectories of physical and 
psychological outcomes and predict which of the identified categories of patients would have 
greater difficulties in their recovery. 
The aim of this research study is to identify one-year trends of patients’ urinary and sexual 
dysfunctions from a clinical and psychological point of view and understand whether 
sociodemographic (i.e., age) and medical variables (i.e., diabetes, BMI, nerve sparing, pre-
surgery scores of urinary incontinence and sexual dysfunction) could differentiate among 
patients following these different one-year longitudinal trajectories. 
2.4.1 Materials and Method 
Participants and Procedure 
An Italian sample of 478 men with localized PC who participated in the Value-Based Project 
and undergone RARP was enrolled at the European Institute of Oncology in Milan between 
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July 2015 and July 2016. Patients were included in the study if they: 1) were diagnosed with 
localized PC, 2) were native Italian speakers, 3) referred to the Value-Based Project and 4) 
had no neurological or psychopathological problems. All eligible men were firstly asked to 
give written informed consent and then were asked to complete the self-report EPIC-26 
survey. At the pre-intervention, sociodemographic and clinical characteristics were also 
collected, in particular age, BMI, presence or not of diabetes, PSA Class, Charlson 
Comorbidity Index, Gleason Score, ASA Class, and preservation or not of the neurovascular 
bundle (nerve-sparing procedure). Clinical characteristics were described in Table 6. They 
completed the EPIC-26 questionnaire at the pre-hospitalization (T0), 45 days (T1) and 3 
(T2), 6 (T3), 9 (T4), and 12 months (T5) after RARP surgery. Since our aim was to study 
the trend of sexual and urinary dysfunction after surgery and we saw that there was low 
outcomes variability among patients before surgery, we excluded the baseline outcomes and 
run the analyses starting from T1, that is 45 days after prostatectomy. Baseline outcomes 
(i.e., urinary incontinence and sexual dysfunction), alongside with sociodemographic and 
other clinical variables, were used to predict patients’ membership in the identified 
longitudinal trajectories of urinary incontinence and sexual dysfunction over time. All 
information and data were collected and analyzed by a multidisciplinary team of the Value-
Based Project. The Ethical Committee of the European Institute of Oncology approved the 
study. 
Table 6. Sample clinical characteristics 
 Sample (%) 
Pre-surgery variables  
Gleason Score   
  ≤ 6 46.1 
  7 39.4 
  8 10.7 
  9-10 3.8 
PSA Class  
  Less than 4 12.8 
  4-10 66.9 
  More than 10 20.3 
ASA Class   
  1 18.7 
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  2-3 81.3 
BMI Class  
  Normal (< 27) 66.7 
  Overweight (≥27) 33.3 
Charlson Index  
  <1 72.8 
  ≥1 27.2 
Surgery variables  
Nerve Sparing  
  No 26.4 
  Unilateral 55.9 
  Bilateral 17.7 
Post-surgery variables  
Complications  
  No 89.3 
  Yes 10.7 
 
Measures 
The Expanded Prostate Cancer Index Composite - Short Form EPIC-26 is the most used 
cancer-specific survey in Urology divisions to measure patient’s well-being[59,92,93]. The 
EPIC-26 is a brief self-report scale, collecting medical and psychological information on 
urinary incontinence, urinary irritation, bowel, sexual and hormonal dysfunction with a 
Likert-scale from 0 to 4 (or 5 in some items). Urinary Incontinence subscale consists of 4 
items investigating leaking urine, urinary control, number of pads used per day and overall 
urinary functioning, in the last 4 weeks. Sexual dysfunction includes items on the ability to 
have an erection, ability to reach an orgasm, quality of erections, frequency of erections, and 
overall sexual function, in the last 4 weeks. Higher scores in subscales indicate the worst 
medical conditions or higher problem perception. The EPIC-26 was administered at the pre-
hospitalization (T0), 45 days (T1) and 3 (T2), 6 (T3), 9 (T4), and 12 months (T5) after RARP 
surgery. 
Age and BMI were collected for each participant at the pre-hospitalization. According to the 
WHO Guidelines[94], a BMI cut-off of 27 divided the sample into two classes: patients with 
a BMI< 27 were included in the “normal weight” class, while those with a BMI≥27 were 
included in the “overweight” class. 
45 
 
Diabetes and the preservation of the neurovascular bundle were included in medical 
variables. Three classes were identified: 1) patients undergone to radical prostatectomy with 
bilateral nerve sparing procedure, 2) patients undergone to radical prostatectomy with 
unilateral nerve sparing, and 3) patients undergone to radical prostatectomy with no nerve 
sparing. 
Statistical Analysis 
To identify different longitudinal trajectories of patients with PC undergone RARP based on 
their initial status and change over time in urinary incontinence and sexual dysfunction, we 
performed a Latent Class Growth Analysis (LCGA) conducted separately for each of these 
two EPIC-26 subscales. The LCGA is a flexible methodology to model patient longitudinal 
trajectories from unobserved subpopulations (i.e., latent trajectory classes) with patient 
variation in growth parameters (e.g., intercept and slope) that are expressed with random 
effects. Another advantage of this methodological approach is that predictors of longitudinal 
trajectory membership could be identified within the LCGA framework by directly 
introducing these independent variables in the model. This permitted to quantify the net 
effect of each predictor whilst adjusting for the other ones and, thus, to better and more 
validly identify the best predictors of longitudinal trajectory membership (for a brief and 
clear overview of LCGA, see Jung & Wickrama, 2008)[95]. The LCGA approach has been 
efficiently adopted to identify trajectories of change over time in quality of life, 
symptomatology, and adjustment to several types of illness, such as heart failure[96], 
depression[97], low back pain[98], and breast cancer[99].  
Non-linear LCGA consisting of intercept, slope and quadratic growth parameters were 
performed with Mplus 8.2. Missing urinary incontinence and sexual dysfunction across 
waves were handled using a robust full information maximum likelihood (FIML) estimation 
procedure. To determine the number of classes to be extracted, we primarily considered the 
Lo-Mendell-Rubin likelihood ratio test (LMR-LRT) following by other statistical 
considerations, such as a successful convergence (i.e., no local maximum likelihood), high 
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entropy value close to 1 (i.e., high precision and certainty in the classification), and total 
count within each classes above 1% (i.e., absence of classes with too few members). 
Specifically, the LMR-LRT compares the solution with k classes with the solution with k-1 
classes; statistically significant values indicate that the broader solution (i.e., k classes) better 
fits the data than the more restricted k-1 classes solution. After determining the number of 
classes to be extracted for the urinary incontinence and sexual dysfunction, clinical and 
sociodemographic predictors of longitudinal change membership were introduced in the 
unconditional LCGA models via multinomial logistic regression. We compared the 
reference class (i.e., high levels of urinary incontinence or sexual dysfunction) with the other 
identified longitudinal trajectories to assess the discriminative power of each clinical and 
sociodemographic predictor in differentiating among the identified longitudinal trajectories. 
Specifically, pre-surgery urinary incontinence score, age, BMI (0=BMI less than 27; 1=BMI 
equal or greater than 27), diabetes (0=no diagnosis of diabetes; 1=diagnosis of diabetes) 
were introduced as predictors to explain membership in longitudinal trajectories of urinary 
incontinence. Pre-surgery sexual dysfunction score, age, and nerve sparing were introduced 
as predictors to explain membership in longitudinal trajectories of sexual dysfunction. 
Because Mplus does not accommodate categorical independent variables, nerve sparing was 
entered as two distinct dummy variables (i.e., unilateral and bilateral nerve sparing; no nerve 
sparing was the reference category). In each model, the worst longitudinal trajectory was 
chosen as the reference category in the multinomial regression model. 
Finally, the association between membership in the two longitudinal trajectories of urinary 
incontinence and sexual dysfunction was assessed by considering the results of a Chi-square 
test and its related contingency table.  
2.4.2 Results 
Identification of Longitudinal Trajectories of Urinary Incontinence 
LCGA was performed on the urinary incontinence scores of the EPIC-26 measured at the 
five time points of the present study. A five-class model with five different longitudinal 
47 
 
trajectories was chosen because the LMR-LRT indicated that the five classes are 
significantly better than four (p =.039) and better than six (p =.266). Moreover, this five-
class solution also displayed a high entropy level (.837) and total count within each class 
above 1% (min=4.65%; max=38.44%). Figure 7 reports the five identified longitudinal 
trajectories of urinary incontinence over time. 
 
Figure 7: The five identified longitudinal trajectories of urinary incontinence 
Patients in the first class (38.44% of the total count) showed the lowest initial status of 
urinary incontinence (intercept=1.25, p<.001) and a moderate recovery over time (slope=-
0.29, p<.001; quadratic=0.03, p<.001). We labeled this longitudinal trajectory as “Class 
1”. As shown in Table 2, 51.4% of patients presented with biopsy Gleason score 6, while in 
2.2% of cases was higher than 8. The majority of patients (67%) had a pre-surgical PSA 
between 4 and 10, and 76.1% had an ASA score between 2 and 3. The Charlson Index was 
lower than 1 in 78.4% of the sample. Moreover, 91.4% of patients who underwent RARP 
and belonging to this Class had no post-surgical complications.  The “Class 2” encompassed 
26.44% of patients with moderate initial levels of urinary incontinence (intercept=2.68, 
p<.001) and a sudden decrease of symptomatology over time (slope=- 0.62, p<.001; 
quadratic=0.05, p<.001). Eighty-five percent of patients belonging to Class 2 had a Gleason 
Score lower than eight, 73.1 % of them had a PSA index varying between 4 and 10, and 
84.2% an ASA score of 2 or 3. Their Charlson Index was lower than 1 in 72.4% of the cases 
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and 89.6% of Class 2 had no complications after surgery (see Table 2). The third class 
(18.32% of the total count), labeled “Class 3”, was characterized by moderate urinary 
incontinence at baseline (intercept=2.72, p<.001) and a moderate recovery over time 
(slope=- 0.27, p<.001; quadratic=0.02, p=.021). Almost 49% of patients presented with 
biopsy Gleason score 6, while in 1.2% of cases was 9 or 10 (see Table 2). The majority of 
patients (60%) had a pre-surgical PSA between 4 and 10, and 83.5% had an ASA score 
between 2 and 3. The Charlson Index was lower than 1 in 68.8% of the sample. Moreover, 
88.8% of patients who underwent RARP and belonging to Class 3 had not post-surgical 
complications. The “Class 4” included 12.14% of patients with a high urinary incontinence 
at 45 after the RARP (intercept=3.46, p<.001) and a moderate recovery over time (slope=- 
0.26, p<.001; quadratic=0.02, p=.059). Eighty-three percent of patients belonging to Class 4 
had a Gleason Score lower than eight, 59.3% of them had a PSA index varying between 4 
and 10, and 84.5% an ASA score of 2 or 3. Their Charlson Index was lower than 1 in 71.2% 
of the cases and 88.1% of Class 4 had not complications after surgery (see Table 7). The last 
class (4.65% of the total count) had the worst initial status of urinary incontinence 
(intercept=3.70, p<.001) with a flat and non-significant linear and quadratic trajectory (linear 
slope=- 0.03, p=.403; quadratic slope=0.00, p=.758). This class could be labelled “Class 5”. 
As shown in Table 2, this Class showed a Gleason Score of 6 in 35% and 7 in 40% of the 
cases, respectively. Seventy-five percent of the patients belonging to Class 5 had a PSA 
index varying from 4 to 10, and 90% of them showed an ASA score of 2 or 3. The Charlson 
index was higher than 1 in 55% of the cases and men of this Class had post-surgical problems 
in 25% of the cases.  
Table 7. Clinical Variables in identified Urinary clusters 
Clinical Variables Class 1 (%) Class 2 (%) Class 3 (%) Class 4 (%) Class 5 (%) 
Gleason Score       
  ≤ 6 51.4 42.5 48.8 39.0 35.0 
  7 35.5 42.5 40.0 44.0 40.0 
  8 10.9 7.5 10.0 13.6 25.0 
  9-10 2.2 7.5 1.2 3.4 0 
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PSA Class      
  Less than 4 14.6 7.5 18.8 11.9 10.0 
  4-10 67.0 73.1 60.0 59.3 75.0 
  More than 10 18.4 19.4 21.2 28.8 15.0 
ASA Class       
  1 23.9 15.8 16.5 15.5 10.0 
  2-3 76.1 84.2 83.5 84.5 90.0 
Charlson Index      
  <1 78.4 72.4 68.8 71.2 45.0 
  ≥1 21.6 27.6 31.2 28.8 55.0 
Complications      
  No 91.4 89.6 88.8 88.1 75.0 
  Yes 8.6 10.4 11.2 11.9 25.0 
 
Sociodemographic and Clinical Predictors of Longitudinal Trajectories of Urinary 
Incontinence 
Then, the predictive role of clinical and sociodemographic variables to explain membership 
in longitudinal trajectories of urinary incontinence was assessed through multinomial 
logistic regression. Specifically, pre-surgery urinary incontinence score, age, BMI, and 
diabetes were introduced in this model as predictors of longitudinal change membership.  
Because “Class 5” was the worst longitudinal trajectory of urinary incontinence over time, 
this class was chosen as the reference category in the multinomial regression model. Results 
showed that more elderly patients (B=-0.09, OR=0.92, p=.004) and higher levels of pre-
surgery incontinence (B=- 1.30, OR=0.27, p=.003) had a lower chance to belong to “Class 
2” compared to “Class 5”. Moreover, compared to “Class 5”, “Class 4” was characterized 
by overweight or obese patients (B=1.04, OR=2.83, p=.035). More elderly patients (B=- 
0.08, OR=0.92, p=.007) with higher levels of pre-surgery incontinence (B=- 2.27, OR=0.10, 
p=.015) had a lower likelihood of being included in “Class 1” than in “Class 5”. Finally, 
compared to the worst longitudinal trajectory of urinary incontinence over time, prostate 
patients within “Class 3” were younger (B=- 0.08, OR=0.92, p=.025) and with less pre-
RARP incontinence (B=- 1.11, OR=0.33, p=.007).   
Diabetes was not helpful to distinguish between patients belonging to the five classes.  
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The analysed sociodemographic and clinical characteristics were not able to distinguish the 
membership between Class 2 and Class 3, even if they have the same characteristics before 
surgery but different trajectories afterwards. 
Identification of Longitudinal Trajectories of Sexual Dysfunction 
LCGA was performed on the sexual dysfunction scores over time. A three-class model with 
three distinct longitudinal trajectories was chosen because the LMR-LRT indicated that the 
three classes are significantly better than two (p<.001) and better than four (p=.404). 
Moreover, this three-class was also supported by a high entropy value (.913) and total count 
within each class above 1% (min=15.49%; max=59.92%). Figure 8 reports these identified 
longitudinal classes of change of sexual dysfunction over time. 
 
Figure 8: The three identified longitudinal trajectories of sexual dysfunction 
Patients in the first class (24.59% of the total count) showed a medium initial level of sexual 
dysfunctionality (intercept=3.54, p<.001) and a moderate recovery over time (slope=- 0.18, 
p<.001; quadratic=0.01, p=.172). We labeled this class as “Class 1”. As shown in Table 3, 
55.1% of patients presented with biopsy Gleason score 6, while 44.9% of cases was 
between7 and 8. The majority of patients (71.2%) had a pre-surgical PSA between 4 and 10, 
and 77.6% had an ASA score between 2 and 3. The Charlson Index was lower than 1 in 
72.9% of the sample. Moreover, 91.5% of patients who underwent RARP and belonging to 
this Class had not post-surgical complications.  “Class 2” encompassed 59.92% of patients 
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with the higher levels of sexual impairment at baseline (intercept=4.34, p<.001) and a flat 
and non-significant recovery over time (slope=0.02, p=.123; quadratic=- 0.01, p=.002). 
Almost eighty-two percent of patients belonging to Class 2 had a Gleason Score lower than 
eight, 63.2 % of them had a PSA index varying between 4 and 10, and 84.2% an ASA score 
of 2 or 3. Their Charlson Index was lower than 1 in 69.4% of the cases and 87.5% of Class 
2 had not complications after surgery (see Table 8). The third class (15.49% of the total 
count), labeled “Class 3”, was characterized by the lowest levels of sexual dysfunction at 45 
days after the RARP (intercept=2.23, p<.001) and a moderate recovery over time (slope=- 
0.11, p=.046; quadratic=0.01, p=.420). Patients belonging to Class 3 showed a biopsy 
Gleason score of 6 in 66.2%, 7 in 26.8% and 8 in 7% of the cases, respectively. Seventy-
five% of patients had a PSA index from 4 to 10 and an ASA score of 2 or 3. Eighty-six 
percent of patients had a Charlson index lower than 1, while almost 93% percent had not 
complications after RARP (See Table 8).  
Table 8. Clinical Variables in identified Sexual clusters 
Clinical Variables Class 1 (%) Class 2 (%) Class 3 (%) 
Gleason Score     
  ≤ 6 55.1 37.6 66.2 
  7 35.6 44.3 26.8 
  8 9.3 12.2 7.0 
  9-10 0 5.9 0 
PSA Class    
  Less than 4 14.4 13.2 8.3 
  4-10 71.2 63.2 75.0 
  More than 10 14.4 23.6 16.7 
ASA Class     
  1 22.4 15.8 24.6 
  2-3 77.6 84.2 75.4 
Charlson Index    
  <1 72.9 69.4 86.1 
  ≥1 27.1 30.6 13.9 
Complications    
  No 91.5 87.5 93.1 
  Yes 8.5 12.5 6.9 
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Clinical Predictors of Longitudinal Trajectories of Sexual Dysfunction 
Then, the predictive role of clinical and sociodemographic variables to explain membership 
in longitudinal trajectories of sexual dysfunction was evaluated through multinomial logistic 
regression. Specifically, pre-surgery sexual dysfunction score, age, and nerve sparing were 
introduced in this model as predictors of longitudinal change membership. 
Because “Class 2” was the worst longitudinal trajectory of sexual dysfunction over time, this 
class was chosen as the reference category in this multinomial regression model. Results 
showed that more elderly patients (B=- 0.08, OR=0.93, p=.004) and a higher level of pre-
surgery sexual symptoms (B=- 1.30, OR=0.27, p<.001) had a lower chance of belonging to 
the “Class 3” compared to the “Class 2”. Nerve sparing procedure was not able to distinguish 
between patients belonging to “Class 2” and “Class 3”. Again, compared to the “Class 2”, 
the “Class 1” was characterized by patients with lower levels of pre-surgery sexual problems 
(B=- 0.89, OR=0.41, p<.001) and subjected to bilateral nerve sparing RARP (B=1.19, 
OR=3.29, p=.028). Age and unilateral nerve sparing RARP did not distinguish between 
patients belonging to “Class 2” and “Class 1”.  
Associations between Membership in Longitudinal Trajectories of Urinary Incontinence and 
Sexual Dysfunction 
The results of the Chi-square test assessing the association between memberships in urinary 
incontinence and sexual dysfunction membership demonstrated that the two cluster 
membership tended to co-occur [Χ2(8, N=478) = 60.20, p<.001]. Specifically, the adjusted 
residual reported in the contingency table (Table 9) demonstrated that patients belonging to 
the “Class 1” of sexual dysfunction had a low chance to be ascribed to the “Class 4” and 
“Class 5” and a high chance to be ascribed to the “Class 1” of urinary incontinence. We 
highlighted a symmetrical and opposite pattern of associations for the “Class 2” of sexual 
dysfunction; specifically, patients in this longitudinal trajectory were more likely to be 
ascribed to “Class 4” and “Class 5” while they had a low likelihood to belong to the “Class 
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1”. Finally, patients in “Class 3” of sexual symptoms had a low likelihood to belong to “Class 
3” and “Class 4” while showing a high probability to be ascribed in “Class 1”. 
Table 9. Contingency table between longitudinal trajectories’ membership of urinary 
incontinence and sexual dysfunction (adjusted residuals within each cell are reported in 
Italics) 
 Urinary Incontinence 
 Class 1 Class 2 Class 3 Class 4 Class5 
S
ex
u
a
l 
D
y
sf
u
n
ct
io
n
 
Class 1 56 
2.2 
34 
0.2 
21 
0.4 
6 
- 2.8 
1 
- 2.1 
Class 2 81 
- 5.8 
82 
0.3 
54 
1.5 
52 
4.7 
19 
3.2 
Class 3 
 
48 
5.3 
18 
- 0.6 
5 
- 2.4 
1 
- 3.1 
0 
- 1.9 
 
2.4.3 Discussion 
This study identifies different longitudinal trajectories of patients with PC underwent RARP 
based on their initial status and change over time in urinary incontinence and sexual 
dysfunction.  
Different trends for each of these two EPIC-26 subscales were identified: five and three 
classes were found for urinary incontinence and sexual dysfunction subscales, respectively. 
All but one of the trajectories of urinary incontinence showed a moderate recovery over one 
year after surgery. Only the class with the worst initial status showed a non-significant 
recovery over time: people who have a high level of urinary incontinence 45 days after 
surgery are likely to have a worse recovery. In fact, the small proportion of patients with 
high urinary incontinence rates at baseline either do not recover, or their symptomatology 
gradually decreases over time. On the contrary, patients with a low level of leaking urine 
after RARP have a faster, and sometimes sudden, recovery. According to the literature[88], 
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these different trends may be affected by sociodemographic and clinical variables, like age, 
pre-surgical condition, and BMI. Elderly and overweight patients may display higher level 
of incontinence 45 days after surgery and may have more problems in the recovery 
trajectories, while those with lower levels of pre-surgery continence seem to have greater 
chance to recover faster and report very small problems one year after RARP.  
Nevertheless, the analysed sociodemographic and clinical variables were not always able to 
predict the membership among different classes. In particular, Class 2 and 3 showed the 
same characteristics before surgery but different trajectories afterwards: other variables 
should be included to distinguish the different classes already at T0. Among the considered 
predictors, no psychological factors were included: it would be necessary to deepen which 
aspects may impact these trends and predict patients’ membership to the identified 
categories. 
Similar to urinary incontinence, sexual dysfunction presents different classes of post-surgery 
condition and recovery. Patients with low and moderate problems 45 days after surgery can 
face a moderate linear recovery, while men with more significant impotence immediately 
after surgery may take a longer period to solve sexual dysfunctions. In fact, most of the 
patients display high level of impotence after RARP and with no recovery of their potency 
even after one year from surgery. Age and the pre-surgical sexual condition are important 
aspects to identify patients with difficulties in recovery from erectile dysfunction. In fact, 
elderly men and patients with sexual impairment before surgery are less likely to recover 
than the others. A recent study with a sample stratified by men’s pre-operative scores of 
erectile function showed that each group statistically and differently improved in potency 
rates at consecutive follow-up visits up to 24 months, proving that the time of recovery varies 
along with patients’ baseline characteristics[91]. Moreover, bilateral nerve-sparing surgical 
intervention seems to positively reduce post-surgery recovery.  
The evaluation of the association between membership in the longitudinal trajectories of 
urinary incontinence and sexual dysfunction may help physicians in the identification of 
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patients with difficulties in the recovery of both symptoms. In fact, some of these patients 
reported both steady problems in sexual function and constant high levels of urinary 
incontinence over time. On the contrary, people with low rates in urinary incontinence more 
probably will also display less level of sexual potency. Sexual and urinary dysfunctions are 
the most common consequences after PC treatments[75] and the displayed association 
underlines the importance of investigating these aspects in clinical practice. In fact, the 
scientific literature shows that sexual life and urinary incontinence are strictly related and 
the most bothersome aspects of incontinence were its effects on partner relationship and 
sexual life[79,82,100].  
These results identify urinary incontinence and sexual dysfunction as the most common and 
unsolved drawbacks after one year from RARP. Even if they show an overall improvement 
over time, one year after RARP no patients’ class has a full recovery and most of the time 
scores down only a point in one year. For this reason, it would be important to analyze cancer 
survivors’ recovery for a longer time in order to better describe the complete process of 
care[101,102]. Research studies on short and long side-effects pointed out that patients still 
suffer from erectile dysfunction, but have a good continence status, even after a median 
follow-up of 42 months after surgery[79]. Moreover, physical impairments negatively 
impact patients’ level of distress, quality of life and life satisfaction even 2- or 3-years after 
diagnosis[86,103]. 
Clinical Implications 
The identification of different longitudinal trajectories of patients with PC undergone RARP 
in urinary incontinence and sexual dysfunction provides new evidence on patients’ recovery 
over the care process. This evidence may be important elements to be discussed during 
patient-physician relationship: urologists may adopt this information to help men make 
informed decisions in line with their individual preference and adjust their expectations 
about long-term sexual life. In fact, physicians’ and patients’ hopes of body function 
recovery do not always concur and great clarity would be needed[104,105].  
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Thanks to the adoption of a person-oriented approach, our results may be useful to identify 
patients at risk and typical trajectories of recovery, which are important prerequisites of 
patient-centered care and planned healthcare programs. A patient-centered approach related 
to multidisciplinary cooperation would be important to overcome medical barriers and 
empower patients, making them aware of their care pathway[106,107]. Along with 
personalized interventions and the development of eHealth platforms to enhance patient’s 
health literacy and engagement[108–110], a new approach to the healthcare system would 
be needed. The implementation of a new healthcare system based on value would help set 
up predictive and individualized care pathways for each cancer diagnosis. The patient would 
be followed along the care process collecting psychological, medical outcomes and 
economic outcomes in order to implement predictive model of care[111–113].  
Limitations 
Several limitations of this study have to be considered. First of all, we were not able to 
conduct a growth mixture modeling (GMM) analysis instead of the LCGA, although a larger 
sample would have been necessary to conduct a GMM. In LCGA we set to 0 the intra-class 
variances of intercepts and slopes, providing a less accurate estimate of the latent trend of 
the dysfunctions’ recovery [114]. Moreover, comorbidities and other possible psychological 
or medical predictors have not been collected. Finally, the measured outcomes were 
collected up to only one year after surgery: it would be important to extend the follow-ups, 
in order to better analyze patient’s recovery of functions, which mostly lasts more than one 
year after treatments[86,88].  
Therefore, our future directions would be to collect more information about patient’s 
characteristics and psychological outcomes through the use of standardized questionnaires 
and semi-structured interviews to provide a more comprehensive framework of the patient 
care process.  
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2.5 Study 2a: Dimensionality and measurement invariance of the Italian version of 
the EORTC QLQ-C30 in postoperative lung cancer patients 
Among a large number of developed instruments to evaluate patient well-being, the 
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire-Core 30 (QLQ-C30) is the most used tool for assessing QoL in cancer-
specific patients[115]. The EORTC QLQ-C30 (Appendix 3) consists of thirty self-reported 
questions assessing different aspects of patient functioning, global health status, and cancer-
related symptoms. More specifically, it is composed of five multi-item functional scales 
(role, physical, cognitive, emotional and social functioning), three multi-item symptom 
scales (fatigue, pain, and nausea  and vomiting), individual items concerning common 
symptoms in cancer patients (dyspnea, insomnia, appetite loss, constipation, diarrhea and 
financial difficulties), and two questions assessing overall QoL. All of the multi-item scales 
and single-item measures range in a score from 0 to 100, where a high score represents a 
higher response level. Thus, a high score for a functional scale implicates a healthy level of 
functioning, while a high score for a symptom scale represents a worse level of 
symptoms[116]. The EORTC QLQ-C30 has been translated in over 110 languages and 
validated in many countries in different samples of cancer patients[117,118]. According to 
a cross-cultural project on a large and heterogeneous sample, the EORTC Quality of Life 
Group reported robust measurement properties across various countries and 
languages[119,120]. In Italy, the questionnaire has been validated only in breast and colon 
cancer patients[121–123], At the same time, other authors investigated the applicability of 
the EORTC QLQ-C30 structure, and positively demonstrated its invariance across different 
cancer sites[124]. Despite these psychometric properties, few scientific articles performed 
factor analysis for validating this tool in lung cancer patients, a clinical area in which the 
EORTC QLQ-C30 is the most used instrument to report patient well-being through the 
different phases of disease[125]. To our knowledge, no published articles investigated the 
psychometric properties and the measurement invariance of the Italian version of the 
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EORTC QLQ-C30 in lung cancer patients. In fact, only four studies measured Quality of 
Life in Italian lung cancer patients through the administration of the EORTC QLQ-C30. Two 
of them were international studies and involved several countries, with all of them focusing 
on non-small cell lung cancer[126–129]. 
The purpose of the current study was to evaluate the factor structure proposed by Costa and 
colleagues[124] for the EORTC QLQ-C30 in a sample of postoperative lung cancer patients 
that underwent lobectomy surgery. Moreover, its measurement invariance across patients of 
varying age, gender, and undergoing robotic or traditional surgery was also evaluated. The 
testing of measurement invariance is a necessary step to further evaluate any inter-individual 
differences.  
2.5.1 Material and methods 
Participants and procedure 
An Italian sample of 167 patients with lung cancer who were also undergoing lobectomy 
was recruited for the Value-Based Project at the European Institute of Oncology in Milan 
between October 2015 and October 2017. Patients were included in the study if they: 1) were 
diagnosed with lung cancer, 2) were native Italian speakers, 3) referred to the Value-Based 
Project and 4) did not have neurological or psychopathological problems. They completed 
the EORTC QLQ-C30 after 30 days from surgery[116,122]. During the doctor’s post-
operative visit, a trained nurse distributed the questionnaire to the patients and they 
completed it using paper and pencil. Informed consent was provided and signed by each 
participant. Participation in the study was voluntary and at each moment, patients could 
withdraw their consent. The study was developed in accordance with the principles stated in 
the Declaration of Helsinki (59th WMA General Assembly, Seoul, 2008) and was approved 
by the European Institute of Oncology Ethical Committee at the European Institute of 
Oncology, Milan.  
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Statistical Analysis  
All statistical analyses were performed using the Maximum Likelihood with Robust 
Standard Errors (MLR) estimation method with Mplus 8.2[130]. The MLR estimator is 
robust to strong departures from univariate and multivariate normality of observed variables. 
The EORTC QLQ-C30 comprises nine multiple-item dimensions and six single items. In 
the first step, the proposed model for the EORTC QLQ-C30 was assessed through CFA. 
Specifically, as reported in Figure 9, the measurement model included the nine multiple item 
dimensions of Physical functioning (5 items), Role functioning (2 items), Emotional 
functioning (4 items), Social functioning (2 items), Cognitive functioning (2 items), Pain (2 
items), Fatigue (3 items), Nausea and vomiting (2 items), and Overall health and quality of 
life (2 items). Following Costa and colleagues[124], the six single-item dimensions (i.e., 
dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) were 
omitted from the tested model. For ease of interpretation, the covariances among latent 
dimensions of QoL were not reported in figure, but they were all estimated in the analyses.  
 
Figure 9: The measurement model for the EORTC QLQ-C30. 
Note: for ease of interpretation, covariances among latent factors are not reported but 
estimated in the CFA model 
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Model fit was assessed by considering five main fit indices. Specifically, a good-fitting 
model was indicated by: a non-significant χ2, a root mean square error of approximation 
(RMSEA) below 0.06, a standardized root mean square residual (SRMR) below 0.80, a 
comparative fit index (CFI) and a Tucker Lewis Index (TLI) above 0.90[64]. Moreover, the 
90% confidence interval for RMSEA was considered to test the null hypothesis of poor 
model fit. Specifically, a good-fitting model was indicated by the upper limit below 0.08 and 
the lower limit close to zero. Finally, we considered the probability of close fit (PCLOSE) 
as well, a one-sided test of the null hypothesis that the model has a close fit (i.e., RMSEA 
equals 0.05). P-value above 0.50 indicated a good-fitting model[131]. 
Then, measurement invariance was evaluated by considering Differential Item Functioning 
(DIF). DIF is a prerequisite for a valid and meaningful comparison of levels of QoL across 
gender, age, and type of surgery (robot-assisted vs. traditional surgery). Specifically, a 
Multiple Indicators-Multiple Causes (MIMIC) was performed to assess differences in the 
measurement model due to age, gender, and type of surgery. A MIMIC model was performed 
because it has specific advantages over Multiple-group Confirmatory Factor Analysis 
(MCFA) in evaluating measurement invariance. Specifically, compared to MCFA, the 
MIMIC model permits to: assess differences in the measurement model due to several 
confounding variables; simultaneously evaluate the role of dichotomous (i.e., robot-assisted 
vs. not robot-assisted surgery and gender) and continuous variables (i.e., age); include 
directly in the model continuous variables without median-splitting, mean-splitting or 
subjective categorization, and test measurement invariance even with small sample size. 
Thus, mainly because of the low sample size, we preferred the MIMIC model over the 
MCFA to assess the structural invariance of the EORTC-QLQ-C30. In the last decade, 
MIMIC model had been adopted to validly test measurement invariance of self-report 
measure of quality of life in asthma[132] and pediatric patients[133], life satisfaction[134], 
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dispositional optimism[135], protective behavioral strategies[136], adolescent burnout[137], 
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The MIMIC Model included the measurement model (i.e., the EORTC QLQ-C30 factor 
structure) plus a structural model assessing DIF. This structural model estimated the effect 
of covariates of gender, age, and type of surgery on latent dimensions of QoL and, thus, 
evaluated differences in these latent factors due to the three considered covariates. The 
structural model included the direct effects of these three covariates on items as well. In a 
first step, these direct effects fixed at zero. Then, modification indices were examined to 
ascertain whether the estimation of any of these direct effects would improve model fit. 
Estimation of direct effects was performed with a stepwise approach: the constraint that 
resulted in the greatest change of χ2 (i.e., highest value of the modification index) were firstly 
estimated. We then continued at freely estimating one direct effect at time until any 
modification was relevant (i.e., Δ χ2 > 3.84). Each significant direct effect was interpreted as 
an indication of DIF: the likelihood to endorse an item was conditional to the specific 
covariate involved in the direct effect. For example, if the direct effect of age on item 1 was 
significant and positive, then the likelihood of endorsing this item differed between patients 
of different age and, specifically, younger people had lower chance to endorse this item. 
Thus, measurement invariance may be strongly impaired when high degree of DIF is 
ascertained. Age was treated as a continuous variable, whereas gender (i.e., Male = 0; Female 
= 1) and type of surgery (i.e., Not robot-assisted surgery = 0; Robot-assisted surgery = 1) 
were binary variables. 
2.5.2 Results 
Sample and item characteristics 
Participants had a mean age of 66.69 ± 7.70 and 100 (59.9%) of them were males. The 
sample underwent lobectomy surgical procedure (N=54; 32.3% with robot-assisted surgery; 
N=113; 67.7% with not robot-assisted surgery). Other clinical variables are reported in Table 
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9. Descriptive statistics of item response (mean, standard deviation, minimum and 
maximum) are reported in Table 10. 
Table 9. Clinical sample characteristics 
 Sample (%) 
ASA Class   
  1 3.6 
  2-3 96.4 
Charlson Index  
  <1 60.5 
  ≥1 39.5 
Robot-assisted surgery  
  No 26.4 
  Yes 55.9 
Complications  
  No 67.1 
  Yes 32.9 
 
Table 10. Descriptive statistics of item response 
Items M SD Min Max 
i1. Do you have any trouble doing strenuous activities, like 
carrying a heavy shopping bag or a suitcase? 
2,16 0,85 1 4 
Ha difficoltà nel fare lavori faticosi, come sollevare una borsa 
della spesa pesante o una valigia? 
 
i2. Do you have any trouble taking a long walk? 
2,171 0,87 1 4 
Ha difficoltà nel fare una lunga passeggiata?  
i3. Do you have any trouble taking a short walk outside of the 
house? 1,396 0,68 1 4 
Ha difficoltà nel fare una breve passeggiata fuori casa? 
 
i4. Do you need to stay in bed or a chair during the day? 
1,799 0,76 1 4 
Ha bisogno di stare a letto o su una sedia durante il giorno?  
i5. Do you need help with eating, dressing, washing yourself or 
using the toilet? 
1,085 0,37 1 4 
Ha bisogno di aiuto per mangiare, vestirsi, lavarsi o andare in 
bagno? 
 
i6. Were you limited in doing either your work or other daily 
activities? 1,915 0,84 1 4 
Ha avuto limitazioni nel fare il Suo lavoro o i lavori di casa?  
i7. Were you limited in pursuing your hobbies or other leisure 
time activities? 
1,857 0,82 1 4 
Ha avuto limitazioni nel praticare i Suoi passatempi- hobby o altre 
attività di divertimento o svago? 
 
i9. Have you had pain? 
1,883 0,85 1 4 
Ha avuto dolore?  
i10. Did you need to rest? 
2,085 0,73 1 4 
Ha avuto bisogno di riposo? 
 
i12. Have you felt weak? 
2,037 0,81 1 4 
Si è sentito debole? 
 
i14. Have you felt nauseated 
1,421 0,69 1 4 
Ha avuto un senso di nausea? 
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i15. Have you vomited? 
1,049 0,29 1 4 
Ha vomitato? 
 
i18. Were you tired?  
2,078 0,74 1 4 
Si è sentito stanco? 
 
i19. Did pain interfere with your daily activities?  
1,723 0,79 1 4 
Il dolore ha interferito con le Sue attività quotidiane? 
 
i20. Have you had difficulty concentrating on things, 
like reading a newspaper or watching television?  
1,265 0,56 1 4 
Ha avuto difficoltà a concentrarsi su cose come leggere un 
giornale o guardare la televisione?  
i21. Did you feel tense?  
1,719 0,74 1 4 
Si è sentito teso?  
i22. Did you worry?  
1,768 0,79 1 4 
Si è preoccupato? 
 
i23. Did you feel irritable?  
1,643 0,74 1 4 
Si è sentito irritabile? 
 
i24. Did you feel depressed?  
1,675 0,86 1 4 
Si è sentito depresso? 
 
i25. Have you had difficulty remembering things? 
1,394 0,63 1 4 
Ha avuto difficoltà a ricordare le cose? 
 
i26. Has your physical condition or medical treatment 
interfered with your family life?  
1,429 0,65 1 4 
Le Sue condizioni fisiche o il Suo trattamento medico hanno 
interferito con la Sua vita familiare? 
 
i27. Has your physical condition or medical treatment 
interfered with your social activities?  
1,582 0,73 1 4 
Le Sue condizioni fisiche o il Suo trattamento medico hanno 
interferito con le Sue attività sociali?  
i29. How would you rate your overall health during the past 
week? 
4,597 1,03 2 7 
Come valuterebbe in generale la Sua salute durante gli ultimi 
sette giorni? 
 
i30. How would you rate your overall quality of life during the 
past week? 
4,636 1,14 2 7 
Come valuterebbe in generale la Sua qualità di vita durante gli 
ultimi sette giorni? 
 
Assessing the Factor Structure 
The proposed measurement model for the EORTC QLQ-C30 showed a good fit [χ2(216, N 
= 167) = 301.48; RMSEA = 0.05; 90% C.I. of RMSEA = 0.04 – 0.06; PCLOSE = .555; CFI 
= 0.95; TLI = .93; SRMR = 0.05). The standardized loadings are displayed in Table 11. As 
reported, all the items had significant loadings and high loadings ranging from .36 to 1.08, 
except for i5 (λ = .17; S.E. = .07; p < .05) and i15 (λ = .13; S.E. = .12; p > .05). Specifically, 
while high scores of pain, fatigue, nausea and vomiting, and physical, role, cognitive, 
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emotional, and social functioning indicated high levels of impairment, high values of overall 
health and quality of life denoted high levels of health-related quality of life. 
Table 11. Standardized factors loading, standard errors and significance for the 
measurement model of the EORTC QLQ-C30. 
 PF RF PA FA NV CF EF SF QL 
i1 
.63 
(.06)*** 
        
i2 
.68 
(.06)*** 
        
i3 
.51 
(.07)*** 
        
i4 
.55 
(.07)*** 
        
i5 
.17 
(.07)* 
        
i6  
.75 
(.05)*** 
       
i7  
.62 
(.07)*** 
       
i9   
.65 
(.06)*** 
      
i19   
.75 
(.06)*** 
      
i10    
.55 
(.06)*** 
     
i12    
.66 
(.06)*** 
     
i18    
.65 
(.06)*** 
     
i14     
.40 
(.17)* 
    
i15     
.13 
(.12) 
    
i20      
.47 
(.09)*** 
   
i25      
.36 
(.09)*** 
   
i21       
.60 
(.06)*** 
  
i22       
.53 
(.08)*** 
  
i23       
.54 
(.08)*** 
  
i24       
.64 
(.08)*** 
  
i26        
.51 
(.08)*** 
 
i27        
.67 
(.07)*** 
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i29         
.92 
(.07)*** 
i30         
1.08 
(.07)*** 
Note: PF = Physical functioning; RF = Role functioning; PA = Pain; FA = Fatigue; NV = 
Nausea and vomiting; CF = Cognitive Functioning; EF = Emotional functioning; SF = 
Social functioning; QL = Overall health and quality of life 
 
Table 12 displays correlations among the nine latent dimensions of QoL. Significant 
correlation coefficients ranged from .24 to .85 in absolute values. These correlations could 
be interpreted as measure of effect size of the associations among latent factors. Following 
suggestion by Cohen[139], the magnitude of these coefficients were interpreted as: weak 
(above .10), moderate (above .30), and strong (above .50). Specifically, weak associations 
were reported between cognitive functioning and physical functioning (r = .29), emotional 
functioning and nausea/vomiting (r = .29), and nausea/vomiting and health-related QoL (r = 
-.24). A grand total of eighteen correlations were large in magnitude. Physical functioning 
and fatigue were the latent dimensions displaying the higher number of strong correlations 
with other factors of QoL. Specifically, physical functioning displayed strong associations 
with pain (r = .54), fatigue (r = .85), health-related QoL (r = -.67), role (r = .77), cognitive 
(r = .51), emotional (r = .50), and social functioning (r = .50). Fatigue showed strong 
associations with health-related QoL (r = -.68), pain (r = .63), nausea/vomiting (r = .51), 
physical (r = .85), role (r = .76), cognitive (r = .59), emotional (r = .62), and social 
functioning (r = .51). Finally, role functioning was the latent dimension of QoL most 
strongly associated with health-related QoL (r = -.72). 
Table 12. Correlations (and their significance) among the nine latent dimensions of the 
EORTC QLQ-C30. 
 PF RF PA FA NV CF EF SF QL 
PF -         
          
RF .77*** -        
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PA .54*** .71*** -       
FA .85*** .76*** .63*** -      
NV .34*** .43* .46*** .51*** -     
CF .51*** .48*** .29** .59*** .30 -    
EF .50*** .52*** .45*** .62*** .29* .41** -   
SF .50*** .54*** .37*** .51*** .08 .50*** .46*** -  
QL -.67*** -.72*** -.57*** -.68*** -.24* -.51*** -.42*** -.43*** - 
Note: PF = Physical functioning; RF = Role functioning; PA = Pain; FA = Fatigue; NV = 
NAuese and vomiting; CF = Cognitive Functioning; EF = Emotional functioning; SF = 
Social functioning; QL = Overall health and quality of life 
 
MIMIC Analysis of Measurement Invariance 
After entering age, gender, and type of surgery in the model, goodness of fit slightly 
remained substantially unchanged [χ2(261, N = 167) = 385.65; RMSEA = 0.05; 90% C.I. of 
RMSEA = 0.04 – 0.06; PCLOSE = .299; CFI = 0.93; TLI = .91; SRMR = 0.05]. The 
standardize factor loadings ranged from .15 to 1.01. Some significant influences of the three 
covariates on latent factors of QoL were reported. Specifically, type of surgery was 
responsible for differences in nausea/vomiting (β = -.52; S.E. = .22; p < .05), pain (β = -.32; 
S.E. = .15; p < .05), and physical (β = -.39; S.E. = .15; p < .01), role (β = -.46; S.E. = .16; p 
< .01), cognitive (β = -.31; S.E. = .15; p < .05), and social functioning (β = -.36; S.E. = .15; 
p < .05). 
The inspection of modification indices suggested that model fit would be improved by freely 
estimated the direct effect of age on item 1 (β = -.03; S.E. = .01; p < .001). After the 
estimation of this effect, the model still showed a good fit [χ2(260, N = 167) = 368.42; 
RMSEA = 0.05; 90% C.I. of RMSEA = 0.04 – 0.06; PCLOSE = .491; CFI = 0.94; TLI = 
.92; SRMR = 0.05]. No other modification indices were relevant. 
After controlling for this DIF, some significant influences of the three covariates on latent 
factors of QoL were reported. Specifically, these influences were the same as the ones 
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reported in the previous MIMIC model (i.e., the model not freely estimating direct effects of 
covariates on items). Specifically, type of surgery was responsible for differences in 
nausea/vomiting (β = -.52; S.E. = .22; p < .05), pain (β = -.32; S.E. = .15; p < .05), and 
physical (β = -.38; S.E. = .15; p < .01), role (β = -.46; S.E. = .16; p < .01), cognitive (β = -
.31; S.E. = .15; p < .05), and social functioning (β = -.36; S.E. = .15; p < .05). The only 
exception was that age directly influenced physical functioning (β = .03; S.E. = .01; p < .01). 
Thus, by comparing this final model with the previous one we may conclude that any bias 
due to DIF is only minimal and not accounting for DIF it may have only trivial consequences 
for the assessment of physical functioning (i.e., the magnitudes of age differences in physical 
functioning were comparable across the two models). 
2.5.3 Discussion 
This study represents an evaluation of the dimensionality and measurement invariance of the 
Italian version of the EORTC QLQ-C30 in a sample of patients with lung cancer who 
underwent lobectomy surgery. Our results demonstrated the validity of the factor structure 
proposed by Costa and his colleagues[124] and thus suggested that the EORTC QLQ-C30 
could be used as a valid measure of quality of life in lung cancer patients undergoing 
lobectomy. In a previous study, Costa and his colleagues[124] proposed and supported this 
measurement model in a sample of cancer patients coming from fourteen countries all over 
the World and considering all the types of cancer(breast, colorectal, gynaecological, head 
and neck, lung, oesophagus/stomach, and prostate cancer). Compared to a previous trial on 
lung cancer patients assessing the changes in QoL over time[140], this study represents the 
first attempt on an Italian sample to evaluate the dimensionality and interindividual 
differences of patients’ QoL with different sociodemographic and clinical characteristics. 
Another study[141] analyzed previously DIF on advanced cancer patients, while the present 
validation article was conducted on lung cancer patients with a primitive diagnosis.  
The questionnaire comprises nine different dimensions. While one factor assesses ‘overall 
health and health-related quality of life’, the remaining eight factors measure distinct 
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symptoms and functioning, namely nausea/vomiting, pain, fatigue for the symptoms’ 
subscales, and physical, role, emotional, cognitive, and social functioning for the functioning 
subscales. All nine subscales were significantly and strongly loaded by their relative items. 
The only exception was nausea and vomiting dimension: one out of its two items exhibited 
a non-significant and very low loading on its factor. Further research is needed to better 
assess the validity of this subscale in evaluating symptoms of nausea and vomiting in lung 
cancer patients and, if necessary, to develop more reliable items to evaluate this kind of 
adverse events.  
Moreover, this study is the first one to evaluate the psychometric properties of the Italian 
version of the EORTC QLQ-C30 in lung cancer patients and assess its measurement 
invariance and DIF due to age, gender and robot-assisted versus not robot-assisted surgery. 
The presence of measurement invariance is one of the necessary steps in efficient and reliable 
evaluation of interindividual differences in QoL within samples of lung cancer patients and 
it represents a prerequisite to validly compare levels of overall health across patients of 
different genders and genders undergoing lobectomy with or without robot-assisted surgery. 
Our main results attested that only one item displayed a trivial DIF. Specifically, compared 
to younger patients, the elderly were more likely to endorse Item 1 (i.e., “Do you have any 
trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?”) on a 
4-point scale (i.e., 1 = “Not at all”; 2 = “A little”;3 = “Quite a bit”; 4 = “Very much”). 
However, the magnitude of this DIF was very small.  
Finally, the last step in the evaluation of DIF involved the assessment of mean differences 
of nine latent scores of QoL across patients of different gender, varying age, and underwent 
robot-assisted or traditional surgery. The main aim of this analysis was to ascertain whether 
not controlling for DIF may lead to consequences for the assessment of QoL (i.e., mean 
differences in QoL differ when controlling or not controlling or DIF). These results 
highlighted that the DIF had only an irrelevant effect on the estimation of differences in 
latent means of QoL among patients. Accidentally, the results coming from this last step also 
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highlighted that younger patients displayed higher levels of physical functioning than elderly 
ones and that robot-assisted surgery may promote better QoL one month after surgery. 
Specifically, compared to patients undergoing traditional surgery, people treated with robot-
assisted surgery displayed lower pain, nausea and vomiting, as well as better physical, role, 
cognitive, and social functioning. This latter result is consistent with empirical evidence 
showing that lung cancer patients treated with robotic thoracic surgery reported reduced 
postoperative pain and complications, fewer functional impairments, and a lower need of 
blood transfusions[142,143]. However, it’s noteworthy that the main aim of this analysis 
was to assess the magnitude and the influence of DIF on mean differences of the nine latent 
scores of QoL; we did not aim at assessing differences due to age, gender, and type of surgery 
on patients’ QoL. Moreover, since we did not balance the baseline characteristics (i.e, QoL 
itself) between patient underwent robot-assisted or traditional surgery, these results may not 
be interpreted in a casual way.  
Limitations 
Current results may be considered in light of some main limitations. Specifically, it was not 
possible to test convergent and/or divergent validity of the EORTC QLQ-C30 due to a lack 
of other self-report measures of patients’ well-being. Nevertheless, a previous Italian 
validation of the questionnaire reported a substantial convergent validity[122], even though 
not in lung cancer patients. Finally, these statistical analyses must be taken with caution due 
to the relatively small sample size. Specifically, as highlighted by Kline (2015), the median 
of typical sample sizes in structural equation modeling studies is about 200 cases. Thus, our 
sample size of 167 lung cancer patients is slightly below this common standard. However, 
lower sample sizes are commonly recruited when the specific population being studied is 
restricted in size and it is difficult to reach higher sample sizes[144]. Thus, while the low 
sample size may represent a limit of our study, this size is a direct consequence of our target 
population. Because of this small sample, structural invariance of the EORTC QLQ-C30 
was assessed by performing MIMIC model and DIF analysis which, compared to MCFA, 
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permit to better test measurement invariance even with small sample size. Future research 
collecting larger samples would be needed to further assess the factor structure of the 
EORTC QLQ-C30 in lung cancer patients underwent lobectomy with or without robot-
assisted surgery. 
Despite these limitations, our findings attested the goodness of the nine-factor structure of 
the Italian version of the EORTC QLQ-C30 in lung cancer patients and its measurement 
invariance in assessing QoL in patients with varying ages, genders, undergoing lobectomy 
with or without robot-assisted surgery. This is also the first study validating a QoL 
questionnaire on lung cancer patients. In fact, other scales have not been already validated 
among Italian lung cancer samples. Additionally, the EORTC QLQ-C30 assesses more 
dimensions related to a cancer diagnosis than other questionnaires. As a practical 
consequence, we advise that nine distinct scores of overall health, pain, fatigue, 
nausea/vomiting, physical, social, role, emotional, and cognitive functioning should be 
computed for evaluating lung cancer patients’ QoL in future research and clinical practice. 
The valid and reliable assessment of adverse events and functioning in lung cancer patients 
is a relevant and prognostic factor in the patient’s recovery. In fact, patient survival is highly 
affected by treatment side-effects such as fatigue, loss of appetite, dyspnea, and coughing, 
as well as physical, psychological, cognitive and social functioning[145–147]. The EORTC 
QLQ-C30 may help healthcare stakeholders in measuring and monitoring QoL in both 
clinical and research fields. In particular, QoL in lung cancer has been studied to understand 
patients’ health status during processes aimed to stop smoking and how it may influence 
patients’ preferences in medical decision-making. It was also used to better investigate 
possible long-term effects of rumination on patients’ recovery and well-being[148,149]. In 
a patient-centered approach, the measurement of QoL would be also important to assess how 
individual differences and cognitive processes may influence patient well-being in different 
medical conditions[106,107,150].  
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In conclusion, the EORTC-QLQ-C30 is a useful and valid self-report tool and it can be used 
to assess interindividual differences of QoL in lung cancer patients in both clinical and 
research contexts.  
2.6 Study 2b: One-year Quality of Life trends in early stage lung cancer patients after 
lobectomy 
Lung cancer is the most common cancer in both genders and the first cause of cancer death 
worldwide. Lung cancer trends are different among countries: Europe has lower trends than 
America[41,151,152]. In Europe, the LucE Report (2016) stated that “more than 312,000 
people were affected by lung cancer every year in the EU”[153]. In Italy, both the incidence 
and mortality rates are decreasing for men and increasing for women[154]. 
Primary malignant lung cancers are classified into two different categories: non-small-cell 
lung cancer (NSCLC) and small-cell lung cancer (SCLC); most lung cancer patients (about 
80%) are diagnosed as NSCLC. Providing an overall 5-year survival rate of 55-77%, a 
resection surgical intervention is the recommended treatment for early stage NSCLC[147]. 
Late diagnosis, comorbidities, and old age often impact on treatment possibilities, by 
reducing the therapeutic options and affecting patients’ Quality of Life (QoL)[155–157]. 
Therefore, treatment efficacy, patient survival, and QoL are strictly related and mutually 
reinforcing. In this perspective, the QoL measurement is necessary to help the stakeholders 
having a more complete framework of patient’s recovery and improving the decision-making 
process of the right treatment without being affected by cognitive biases[146,158,159]. 
The scientific literature shows indeed that Health-Related Quality of Life (HRQoL) 
outcome, before and after surgery, is an important predictor of patient’s recovery and 
survival in lung cancer patients[146,160,161]. A systematic review (2009)[162] analyzing 
this association, reported that most of the included articles indicate overall QoL, functional 
dysfunctions, and symptoms (e.g. pain, fatigue, and appetite loss) - adjusted for different 
sociodemographic and clinical characteristics - as prognostic factors of patients’ 
survivorship. In fact, a high survival rate is associated with better patients’ well-being, higher 
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motivation, and engagement in doing physical activities, and greater pulmonary 
function[163–166]. Monitoring patients’ QoL after surgery and identifying its predictors is 
therefore important to guarantee better survivorship: several studies showed that patients 
who underwent surgery often reported a worsening in QoL after treatment[167]. In 
particular, Yang and colleagues (2012) showed that 35% of long-term lung cancer survivors 
had a significant decline in overall QoL related to a worse level of fatigue, pain, dyspnea, 
appetite, and cough[168]. Also disturbed sleep and distress affect QoL over time[169]. 
Another article (2013) analyzed demographic and clinical characteristics as predictors of 
QoL in lung cancer survivors and reported that younger participants showed more fatigue, 
dyspnea, and stress for financial problems. Patients with cancer-related comorbidities 
reported less severe dysphagia, nausea and vomiting[163]. According to the type of surgery, 
patients take 6 to 12 months to return to their preoperative HRQoL status[170,171]. The 
video-assisted thoracoscopic surgery (VATS) implies a faster recovery and better QoL in 
NSCLC patients than the thoracotomy one year after surgery[172]. Moreover, patients 
undergoing VATS were faster released from the hospital and reported less post-operative 
pain and complications than those who underwent traditional thoracotomy[173]. 
To our knowledge, only one previous research article studied the trajectories of lung cancer 
patients’ QoL for a two-year period after surgery. Kenny et al. (2008)[167] showed that 65% 
of the recruited sample survived for 2 years after surgery and in that period of time HRQoL 
improved for patients with no recurrence, despite half of them continued to experience 
severe symptoms and functional limitations[167]. Nevertheless, the authors did not stratify 
for surgery type and did not study which sociodemographic or clinical characteristics may 
predict the QoL trend over time. For this reason, the aim of the study is to identify one-year 
trends of lung cancer patients’ QoL after robot-assisted or traditional surgery and investigate 
whether clinical (e.g. pre-surgery QoL, type of surgery, and perioperative complications) 
and sociodemographic variables (e.g. age) may predict these trends. 
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2.6.1 Materials and Methods 
Participants and Procedure 
An Italian sample of 176 patients who underwent pulmonary lobectomy using the robotic-
assisted approach or traditional open technique for lung cancer and participated in the Value-
Based Project were enrolled at the European Institute of Oncology in Milan between October 
2015 and November 2017. Patients were included into the study if they: 1) were diagnosed 
with primary early stage NSCLC (stage I and II), 2) were native Italian speakers, 3) were 
candidate to pulmonary lobectomy, and 4) had not neurological or psychopathological 
problems. Patients with cancer recurrences or with a previous thoracic surgical treatment 
were excluded from the study. All eligible patients were firstly asked to give written 
informed consent and then were asked to complete the EORTC QLQ-C30 questionnaire. 
They completed the EORTC QLQ-C30 at the pre-hospitalization (t0), 30 days (t1), 4 months 
(t2), 8 months (t3) and 12 months (t4) after lobectomy surgery.  
Sociodemographic (i.e. age and gender) and clinical (i.e., perioperative complications: 0 = 
No perioperative complications; 1 = Perioperative complications; Type of surgery: 0 = 
Traditional lobectomy; 1 = Robot-assisted lobectomy) variables were also collected. 
Patients’ sociodemographic and clinical characteristics are described in Table 13.  
Table 13. Baseline characteristics of participants 
Variables Descriptive statistics 
Age, years [mean (SD)] 66.71 (7.68) 
Gender [N (%)] 
Female 
Male 
 
70 (39.8%) 
106 (60.2%) 
Type of surgery [N (%)] 
Traditional lobectomy 
Robot-assisted lobectomy 
 
117 (66.5%) 
59 (33.5%) 
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Perioperative complications [N (%)] 
Yes 
No 
 
59 (33.5%) 
117 (66.5%) 
Education [N (%)] 
< High school 
High school or equivalent 
> High school 
Unknown 
 
70 (39.7%) 
73 (41.5%) 
22 (12.5%) 
11 (6.3%) 
 
Most patients have completed data at every follow-up (55.7%). The 18.2% had missing data 
at one follow-up, 14.8% at two follow ups, and 11.4% at three follow-ups. All data were 
collected and analyzed by a multidisciplinary team of the Value-Based Project. The study 
was developed in accordance with the principles stated in the Declaration of Helsinki (59th 
WMA General Assembly, Seoul, 2008) and was approved by the European Institute of 
Oncology Ethical Committee at the European Institute of Oncology, Milan. The participation 
in the study was voluntary and the patients could withdraw their consent at any time. 
Measures 
The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire-Core 30 (QLQ-C30) is the most used tool for measuring QoL in lung cancer 
patients[115,174].  
The EORTC QLQ-C30 consists of thirty self-reported questions assessing different aspects 
of patient functioning, global health status, and cancer-related symptoms. More specifically, 
it is composed of five multi-item functional scales (role, physical, cognitive, emotional and 
social functioning), three multi-item symptom scales (fatigue, pain, and nausea and 
vomiting), individual items concerning common symptoms in cancer patients (dyspnea, 
insomnia, appetite loss, constipation, diarrhea and financial difficulties), and two questions 
assessing overall QoL. All of the multi-item scales and single-item measures range in a score 
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from 0 to 100Specifically, a high score for a functional scale and overall QoL implicates a 
healthy level of functioning and global health status, while a high score for a symptom scale 
represents worse symptomatology[116]. 
Statistical Analysis 
Analyses were conducted using SPSS (Statistical Package for the Social Sciences), version 
25. Individual growth curve (IGCs) models with the SPSS MIXED procedure were 
performed to evaluate trends of post-operative QoL across time and to assess the influence 
of pre-surgery QoL, type of surgery, perioperative complications and age on trends of QoL. 
IGC has several advantages in analyzing longitudinal data over traditional statistical 
methodologies, such as generalized linear models or analysis of variance. Specifically, ICG 
models allow one to validly analyze data that, as longitudinal data, violates the assumption 
of independence of observations. ICG models were performed by following guidelines by 
Singer and Willet (2003)[175] and Shek and Ma (2011)[176] to validly assess longitudinal 
trends and interindividual differences in intraindividual changes over time. Specifically, the 
data were analyzed by using mixed effect models with maximum likelihood (ML) 
estimation. This method allowed to model individual change over time, determine the shape 
of the growth curves, and explored systematic differences in change by examining the effects 
of covariates (i.e., pre-surgery QoL, type of surgery, perioperative complications, and age) 
on QoL initial status and rate of growth. Each of the 15 EORTC-QLQ-C30 dimensions was 
analyzed separately in four consecutive steps. 
In the first step, an unconditional mean model (i.e., Model 1) was tested. This is a one-way 
ANOVA model with a random effect with no predictors included. It served as a baseline 
model and assessed the intraclass correlation coefficient (ICC). ICC describes the amount of 
variance in each of the QoL dimensions that is attributed to differences between patients and 
it evaluates the necessity of performing mixed model instead of traditional methods (e.g., 
ANOVA). Generally, ICC of 0.25 or above indicates the necessity of performing 
longitudinal analysis with repeated measure mixed models. 
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The second step involved performing an unconditional linear growth model (Model 2) that 
explored linear individual variations in trends of QoL over time and served as a baseline 
model to assess whether the growth curve of QoL was linear or curvilinear. In the third step, 
an unconditional quadratic growth model (Model 3) was performed to assess whether the 
rate of change accelerated or decelerated across time following a parabola-shape. 
Random effect for intercept was estimated in all the models; random effect for linear change 
was estimated as well in Model 2 and Model 3. All these models were performed by fitting 
an unstructured (UN) covariance matrix for the random effects. Akaike Information 
Criterion (AIC) and -2log likelihood (-2LL) were considered to ascertain which of these 
three models were more appropriate to describe the change of each of the QoL dimensions 
over time. Specifically, the best fitting model was indicated by lower values of AIC. 
Moreover, a statistically significant likelihood ratio test between a smaller model (i.e., lower 
number of estimated effects/parameters) versus a more complex model indicated that the 
larger model provided a significant improvement in model fitting over the smaller one. Then, 
the best fitting model was subsequently retained and tested in the following steps. 
Specifically, in the last step, conditional models were performed to test whether pre-surgery 
QoL, age, type of surgery, and perioperative complications influenced initial QoL status at 
t1, linear growth rate, and quadratic change. Continuous variables (i.e., age and pre-surgery 
QoL) were grand mean centered, whereas perioperative complications and type of surgery 
were dummy coded (i.e., perioperative complications: 0 = No perioperative complications, 
1 = Perioperative complications; Type of surgery: 0 = Traditional lobectomy, 1 = Robot-
assisted lobectomy). Three different covariance structure models were performed to assess 
the error covariance structure: Model 4, conditional model with unstructured (UN) 
covariance structure, Model 5 conditional model with compound symmetry (CS) covariance 
structure, and Model 6, conditional model with first-order autoregressive (AR1) covariance 
structure. Once again, the best fitting model was identified by considering AIC and 
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likelihood ratio test. In all the three models, the intercept and the slope were allowed to vary 
within individuals. 
2.6.2 Results 
Table 14 shows AIC, -2LL and results of likelihood ratio tests for tested models for each of 
the 15 dimensions of QoL. ICC for Model 1 is reported as well. As reported, all ICC were 
above .25 and ranged from .26 to .65. These results attested that it was necessary to perform 
longitudinal analysis with repeated measure mixed models for all the 15 considered 
dimensions of QoL. 
Table 14. ICC, AIC, -2LL and results of likelihood ratio tests for tested models (underlined 
the best fitting model among M1, M2, and M3; in italics, the best fitting model among M4, 
M5 and M6). 
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QoL Model ICC AIC -2LL #EP Comparison Δ-2LL Δdf p 
GHS M1 .50 4461.49 4455.49 3 - - - - 
 M2 - 4407.33 4395.33 6 M1-M2 60.16 3 *** 
 M3 - 4399.45 4385.45 7 M2-M3 9.88 1 ** 
 M4 - 4282.58 4232.58 25 - - - - 
 M5 - 4303.05 4269.05 17 M4-M5 36.47 8 *** 
 M6 - 4276.52 4242.52 17 M4-M6 9.94 8 n.s. 
PF M1 .60 4464.18 4458.18 3 - - - - 
 M2 - 4445.56 4433.56 6 M1-M2 24.63 3 *** 
 M3 - 4420.28 4406.28 7 M2-M3 27.28 1 *** 
 M4 - 4225.07 4175.07 25 - - - - 
 M5 - 4242.02 4208.02 17 M4-M5 32.95 8 *** 
 M6 - 4253.14 4219.14 17 M4-M6 44.07 8 *** 
RF M1 .54 4867.23 4861.23 3 - - - - 
 M2 - 4831.91 4819.91 6 M1-M2 41.33 3 *** 
 M3 - 4810.66 4796.66 7 M2-M3 23.25 1 *** 
 M4 - 4604.95 4554.95 25 - - - - 
 M5 - 4614.12 4580.12 17 M4-M5 25.17 8 ** 
 M6 - 4621.59 4587.59 17 M4-M6 32.64 8 *** 
EF M1 .53 4422.01 4416.01 3 - - - - 
 M2 - 4386.90 4374.90 6 M1-M2 41.12 3 *** 
 M3 - 4387.88 4373.88 7 M2-M3 1.02 1 n.s. 
 M4 - 4138.71 4098.71 20 - - - - 
 M5 - 4155.16 4131.16 12 M4-M5 32.45 8 *** 
 M6 - 4135.03 4111.03 12 M4-M6 12.32 8 n.s. 
79 
 
PA M1 .54 4570.56 4564.56 3 - - - - 
 M2 - 4530.85 4518.85 6 M1-M2 45.71 3 *** 
CF M1 .65 4274.46 4268.46 3 - - - - 
 M2 - 4250.06 4238.06 6 M1-M2 30.40 3 *** 
 M3 - 4252.01 4238.01 7 M2-M3 0.05 1 n.s. 
 M4 - 4074.94 4034.94 20 - - - - 
 M5 - 4091.37 4067.37 12 M4-M5 32.43 8 *** 
 M6 - 4090.10 4066.10 12 M4-M6 31.16 8 *** 
SF M1 .52 4495.40 4489.40 3 - - - - 
 M2 - 4482.41 4470.41 6 M1-M2 18.99 3 *** 
 M3 - 4481.66 4467.66 7 M2-M3 2.74 1 n.s. 
 M4 - 4376.62 4336.62 20 - - - - 
 M5 - 4376.09 4352.09 12 M4-M5 15.48 8 n.s. 
 M6 - 4386.86 4362.86 12 M4-M6 26.24 8 ** 
FA M1 .61 4533.00 4527.00 3 - - - - 
 M2 - 4500.74 4488.74 6 M1-M2 38.26 3 *** 
 M3 - 4482.64 4468.64 7 M2-M3 20.10 1 *** 
 M4 - 4268.79 4218.79 25 - - - - 
 M5 - 4259.61 4225.61 17 M4-M5 6.82 8 n.s. 
 M6 - 4287.78 4253.78 17 M4-M6 34.99 8 ** 
NV M1 .43 4271.99 4265.99 3 - - - - 
 M2 - 4235.73 4223.73 6 M1-M2 42.27 3 *** 
 M3 - 4233.48 4219.48 7 M2-M3 4.25 1 * 
 M4 - 4065.67 4015.67 25 - - - - 
 M5 - 4134.39 4100.40 17 M4-M5 84.72 8 *** 
 M6 - 4122.28 4088.28 17 M4-M6 72.60 8 *** 
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 M3 - 4523.99 4509.99 7 M2-M3 8.86 1 ** 
 M4 - 4159.21 4109.21 25 - - - - 
 M5 - 4186.29 4152.29 17 M4-M5 43.07 8 *** 
 M6 - 4193.91 4159.91 17 M4-M6 50.70 8 *** 
DY M1 .38 4987.10 4981.10 3 - - - - 
 M2 - 4980.15 4968.15 6 M1-M2 12.95 3 ** 
 M3 - 4976.78 4962.78 7 M2-M3 5.37 1 * 
 M4 - 4789.35 4739.35 25 - - - - 
 M5 - 4780.63 4746.63 17 M4-M5 7.28 8 n.s. 
 M6 - 4792.89 4758.89 17 M4-M6 19.54 8 ** 
IN M1 .55 5041.78 5035.78 3 - - - - 
 M2 - 5024.71 5012.71 6 M1-M2 23.07 3 *** 
 M3 - 5013.63 4999.63 7 M2-M3 13.08 1 *** 
 M4 - 4832.47 4782.47 25 - - - - 
 M5 - 4841.44 4807.44 17 M4-M5 24.97 8 ** 
 M6 - 4831.96 4797.96 17 M4-M6 15.48 8 n.s. 
AS M1 .46 4996.77 4990.77 3 - - - - 
 M2 - 4934.42 4922.42 6 M1-M2 68.35 3 *** 
 M3 - 4923.87 4909.87 7 M2-M3 12.55 1 *** 
 M4 - 4727.52 4677.52 25 - - - - 
 M5 - 4764.70 4730.70 17 M4-M5 53.17 8 *** 
 M6 - 4746.70 4712.70 17 M4-M6 35.18 8 *** 
CO M1 .48 4848.39 4842.39 3 - - - - 
 M2 - 4799.54 4787.54 6 M1-M2 54.85 3 *** 
 M3 - 4793.15 4779.15 7 M2-M3 8.39 1 *** 
 M4 - 4675.50 4625.50 25 - - - - 
 M5 - 4716.71 4682.71 17 M4-M5 57.21 8 *** 
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 M6 - 4702.85 4668.85 17 M4-M6 43.35 8 *** 
DI M1 .26 4333.62 4327.62 3 - - - - 
 M2 - 4313.64 4301.64 6 M1-M2 25.97 3 *** 
 M3 - 4315.12 4301.12 7 M2-M3 0.52 1 n.s. 
 M4 - 4260.42 4220.42 20 - - - - 
 M5 - 4273.76 4249.76 12 M4-M5 22.17 8 *** 
 M6 - 4261.01 4237.01 12 M4-M6 9.42 8 * 
FD M1 .56 4614.05 4608.05 3 - - - - 
 M2 - 4610.34 4598.34 6 M1-M2 9.71 3 * 
 M3 - 4612.34 4598.34 7 M2-M3 0.00 1 n.s. 
 M4 - 4472.48 4432.48 20 - - - - 
 M5 - 4488.43 4464.43 12 M4-M5 31.95 8 *** 
 M6 - 4514.41 4490.41 12 M4-M6 57.93 8 *** 
Note: GHS = Global health status; PF = Physical functioning; RL = Role functioning; EF 
= Emotional functioning; CF = Cognitive functioning; SF = Social functioning; FA = 
Fatigue; NV = Nausea and vomiting; PA = Pain; DY = Dyspnoea; IN = Insomnia; AS = 
Appetite loss; CO =Constipation; DI = Diarrhoea; FD = Financial difficulties; ICC = 
Intraclass correlation; AIC = Akaike Information Criterion; -2LL = -2log likelihood; #EP 
= Number of estimated parameters; Δ-2LL = Differences in -2log likelihood between 
compared models; Δdf = Differences in number of estimated parameters/degrees of freedom 
 
Global Health Status 
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of global health status and linear and quadratic trajectories over time. Thus, this 
model was retained in subsequent analyses to test whether pre-surgery global health status, 
age, type of surgery, and perioperative complications influenced initial QoL status at t1, 
linear growth rate, and quadratic change and to compare the three error covariance structures. 
Model 6 with AR1 covariance structure showed the best fit. Table 15 reports the final model 
with fixed effects for all the 15 dimensions of QoL. As shown, the initial level of global 
health status at t1 was 60.40 (S.E.=2.05; p<.001) and it increased linearly over time (B= 
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2.07; S.E. = 0.71; p < .01). However, the rate of quadratic change was not significant (B = -
0.10; S.E. = 0.06; n.s.). Patients with higher level of pre-surgery global health status showed 
higher subsequent level at t1 (B = 0.13; S.E. = 0.19; p < .05). As shown in Figure 10A, 
patients with higher level of pre-surgery global health status reported a positive linear trend 
(B=0.04; S.E.= 0.03; p< .05) indicating that their GHS increase more over time, and a 
negative quadratic rate of change indicating that their rate of growth decelerated more over 
time (B = -0.01; S.E. = 0.01; p < .05). On the contrary, the rate of quadratic change was 
negative for patients experiencing perioperative complications (B = -0.20; S.E. = 0.09; p < 
.05) indicating that their increasing effect gradually diminished more over time (Figure 10B)
Table 15. Fixed effects for all the 15 dimensions of QoL. 
 GHS PF RF EF CF SF FA NV 
Intercept 60.40 (2.05) 
*** 
77.05 (1.78) 
*** 
71.85 (2.54) 
*** 
76.18 (2.00) 
*** 
88.28 (1.51) 
*** 
82.49 (2.01) 
*** 
33.08 (2.22) 
*** 
8.93 (1.47) 
*** 
Time 2.07 (0.71) 
** 
2.36 (0.53) 
*** 
3.10 (0.79) 
*** 
0.69 (0.27) 
* 
-0.34 (0.19) 
n.s. 
0.74 (0.22) 
** 
-2.56 (0.73) 
** 
-1.18 (0.41) 
** 
TimeQ -0.10 (0.06) 
n.s. 
-0.17 (0.05) 
*** 
-0.20 (0.07) 
** 
- - - 0.15 (0.07) 
* 
0.07 (0.04) 
n.s. 
T0  0.13 (0.07) 
* 
0.52 (0.10) 
*** 
0.41 (0.10) 
*** 
0.48 (0.07) 
*** 
0.50 (0.06) 
*** 
0.35 (0.09) 
*** 
0.52 (0.08) 
*** 
0.12 (0.16) 
n.s. 
TS at t0 4.69 (3.07) 
n.s. 
4.66 (2.70) 
n.s. 
7.04 (3.81) 
n.s. 
3.80 (2.97) 
n.s. 
3.37 (2.25) 
n.s. 
5.40 (2.95) 
n.s. 
-0.37 (3.36) 
n.s. 
-4.23 (2.22) 
n.s. 
PC -4.64 (3.08) 
n.s. 
-6.30 (2.73) 
* 
-7.91 (2.87) 
* 
-1.79 (2.98) 
n.s. 
-1.00 (2.24) 
n.s. 
-2.58 (3.00) 
n.s. 
8.01 (3.35) 
* 
0.11 (2.24) 
n.s. 
Age -0.13 (0.19) 
n.s. 
-0.14 (0.17) 
n.s 
0.32 (0.23) 
n.s. 
-0.13 (0.18) 
n.s. 
-0.16 (0.14) 
n.s. 
0.28 (0.18) 
n.s. 
0.17 (0.20) 
n.s. 
-0.10 (0.13) 
n.s. 
Time*t0 
QoL 
0.05 (0.02) 
* 
0.01 (0.03) 
n.s. 
-0.04 (0.03) 
n.s. 
-0.02 (0.01) 
** 
-0.01 (0.01) 
n.s. 
-0.02 (0.01) 
n.s. 
-0.05 (0.03) 
n.s. 
-0.07 (0.04) 
n.s. 
Time*TS -1.17 (1.03) 
n.s. 
-1.94 (0.80) 
* 
-1.78 (1.18) 
n.s. 
-0.49 (0.40) 
n.s. 
0.11 (0.28) 
n.s. 
-0.08 (0.33) 
n.s. 
0.35 (1.09) 
n.s. 
0.55 (0.62) 
n.s. 
Time*PC 1.76 (1.05) 
n.s. 
1.49 (0.83) 
n.s. 
3.27 (1.21) 
** 
-0.67 (0.41) 
n.s. 
0.00 (0.29) 
n.s. 
-0.40 (0.34) 
n.s. 
-2.01 (1.10) 
n.s. 
-0.33 (0.63) 
n.s. 
Time*Age -0.04 (0.07) 
n.s. 
0.15 (0.05) 
n.s. 
-0.09 (0.07) 
n.s. 
0.02 (0.02) 
n.s. 
0.01 (0.02) 
n.s. 
-0.02 (0.02) 
n.s. 
0.01 (0.07) 
n.s. 
-0.02 (0.04) 
n.s. 
TimeQ*t0 
QoL 
-0.01 (0.00) 
* 
-0.00 (0.00) 
n.s. 
0.00 (0.00) 
n.s. 
- - - 0.00 (0.00) 
n.s. 
0.01 (0.00) 
n.s. 
TimeQ*TS 0.11 (0.09) 
n.s. 
0.18 (0.07) 
* 
0.19 (0.10) 
n.s. 
- - - -0.06 (0.10) 
n.s. 
-0.04 (0.06) 
n.s. 
TimeQ*PC -0.20 (0.09) 
* 
-0.14 (0.70) 
n.s. 
-0.32 (0.11) 
** 
- - - 0.22 (0.10) 
* 
0.05 (0.06) 
n.s. 
TimeQ*Age 0.01 (0.01) 
n.s. 
0.00 (0.00) 
n.s. 
0.01 (0.01) 
n.s 
- - - -0.00 (0.00) 
n.s. 
0.00 (0.00) 
n.s. 
1 
 
 
 PA DY IN AS CO DI FD 
Intercept 23.60 (2.39) 
*** 
29.95 (2.37) 
*** 
28.11 (2.76) 
*** 
26.63 (3.07) 
*** 
27.73 (3.15) 
*** 
6.73 (1.57) 
*** 
12.57 (2.03) 
*** 
Time -1.58 (0.79) 
* 
-0.77 (0.97) 
n.s. 
-3.73 (0.93) 
*** 
-4.39 (0.88) 
*** 
-2.89 (0.98) 
** 
-0.11 (0.24) 
n.s. 
-0.03 (0.25) 
n.s. 
TimeQ 0.06 (0.06) 
n.s. 
0.03 (0.09) 
n.s. 
0.24 (0.08) 
** 
0.24 (0.08) 
** 
0.15 (0.08) 
n.s. 
- - 
T0  0.47 (0.11) 
*** 
0.42 (0.09) 
*** 
0.28 (0.08) 
*** 
.23 (0.13) 
n.s. 
0.56 (0.09) 
*** 
0.37 (0.08) 
*** 
0.42 (0.06) 
*** 
TS at t0 -1.35 (3.61) 
n.s. 
-4.04 (2.52) 
n.s. 
-5.01 (4.11) 
n.s. 
12.17 (4.56) 
** 
-6.41 (4.69) 
n.s. 
-2.36 (2.33) 
n.s. 
-2.4 (2.98) 
n.s. 
PC 4.84 (3.71) 
n.s. 
9.41 (3.59) 
** 
-0.87 (4.23) 
n.s. 
-4.14 (4.65) 
n.s. 
2.83 (4.70) 
n.s. 
-2.88 (2.35) 
n.s. 
0.69 (3.00) 
n.s. 
Age -0.34 (0.22) 
n.s. 
-0.21 (0.22) 
n.s. 
-0.13 (0.25) 
n.s. 
0.26 (0.28) 
n.s. 
0.33 (.029) 
n.s. 
-0.22 (0.14) 
n.s. 
-0.40 (0.18) 
* 
Time*t0 
QoL 
-0.06 (0.03) 
n.s. 
-0.00 (0.04) 
n.s. 
-0.01 (0.03) 
n.s. 
-0.05 (0.04) 
n.s. 
-0.08 (0.03) 
** 
-0.02 (0.1) 
* 
0.00 (0.01) 
n.s. 
Time*TS -1.45 (1.61) 
n.s. 
0.22 (1.42) 
n.s. 
3.37 (1.38) 
* 
3.01 (1.31) 
* 
1.00 (1.42) 
n.s. 
0.14 (0.35) 
n.s. 
-0.21 (0.37) 
n.s. 
Time*PC 0.37 (1.22) 
n.s. 
-4.06 (1.50) 
** 
0.38 (1.42) 
n.s. 
0.78 (1.34) 
n.s. 
-0.53 (1.44) 
n.s. 
0.35 (0.35) 
n.s. 
0.88 (0.37) 
* 
Time*Age 0.02 (0.07) 
n.s. 
0.09 (0.09) 
n.s. 
-0.10 (0.09) 
n.s. 
-0.07 (0.08) 
n.s. 
0.07 (0.09) 
n.s. 
0.04 (0.02) 
n.s. 
0.04 (003) 
n.s. 
TimeQ*t0 
QoL 
0.01 (0.00) 
n.s. 
-0.00 (0.00) 
n.s. 
0.00 (0.00) 
n.s. 
0.00 (0.00) 
n.s. 
0.01 (0.00) 
** 
- - 
TimeQ*TS 0.14 (0.10) 
n.s. 
-0.08 (0.13) 
n.s. 
-0.24 (0.12) 
* 
-0.20 (0.11) 
n.s. 
-0.1 (0.12) 
n.s. 
- - 
TimeQ*PC -0.03 (0.10) 
n.s. 
0.37 (0.13) 
** 
0.09 (0.12) 
n.s. 
0.07 (0.12) 
n.s. 
0.02 (0.12) 
n.s. 
- - 
TimeQ*Age 0.00 (0.0) 
n.s. 
-0.01 (0.01) 
n.s. 
0.01 (0.01) 
n.s. 
0.01 (0.01) 
n.s. 
-0.01 (0.01) 
n.s. 
- - 
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Note: GHS = Global health status; PF = Physical functioning; RL = Role functioning; EF = Emotional functioning; CF = Cognitive functioning; SF = 
Social functioning; FA = Fatigue; NV = Nausea and vomiting; PA = Pain; DY = Dyspnoea; IN = Insomnia; AS = Appetite loss; CO =Constipation; DI 
= Diarrhoea; FD = Financial difficulties; Time = Linear rate of growth; TimeQ = Quadratic rate of growth; T0 = pre-surgery subscales score; TS = 
type of surgery at t0; PC = Perioperative complications.
3 
 
Physical Functioning  
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of physical functioning, and linear and quadratic trajectories over time. Model 4 
with UN covariance structure showed the best fit. As shown, the initial level of physical 
functioning at t1 was 77.05 (S.E. = 1.78; p < .001), increased linearly (B = 2.36; S.E. = 0.53; 
p < .001) and decelerated over time (B = -0.17; S.E. = 0.05; p < .001). Patients with higher 
pre-surgery physical functioning level (B = 0.52; S.E. = 0.10; p < .001) and without 
perioperative complications (B = -6.30; S.E. = 2.73; p < .01) showed higher subsequent level 
at t1. Type of surgery moderated rates of both linear and quadratic change. Specifically, as 
shown in Figure 10C, patients undergoing robot-assisted surgery, compared to patients 
undergoing traditional surgery, reported a slower linear increase (B = -1.94, S.E. = 0.80; p < 
.05) but the positive quadratic effect (B = 0.18; S.E. = 0.07; p < .05) indicated that their rate 
of change decelerated less over time. 
Role Functioning 
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of role functioning, and linear and quadratic trajectories over time. Model 4 with 
UN covariance structure showed the best fit. A t1, the level of role functioning was 71.85 
(S.E. = 2.54; p < .001), increased linearly (B = 3.10; S.E. = 0.79; p < .001) and decelerated 
over time (B = -0.20; S.E. = 0.07; p < .01). Patients with higher pre-surgery role functioning 
level (B = 0.41; S.E. = 0.10; p < .001) and without perioperative complications (B = -7.91; 
S.E. = 3.87; p < .01) showed higher level of role functioning at t1. The experiencing of 
perioperative complications moderated rates of both linear and quadratic change of role 
functioning. Specifically, as shown in Figure 10D, patients with perioperative complications, 
compared to patients without complications, reported a faster increase (B = 3.27; S.E. = 1.21; 
p < .001) but this increasing effect gradually diminished more (B = -0.32; S.E. = 0.11; p < 
.01) over time. 
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Emotional Functioning 
The best fit of Model 2 attested that there were significant between-subject variations in the 
initial level of emotional functioning and linear trajectories over time. Model 6 with AR1 
covariance structure showed the best fit. Emotional functioning at t1 was 76.18 (S.E. = 2.00; 
p < .001) and increased linearly over time (B = 0.69; S.E. = 0.27; p < .01). Patients with 
higher pre-surgery emotional functioning level (B = 0.48; S.E. = 0.10; p < .001) showed 
higher level at t1. Moreover, level of pre-surgery emotional functioning moderated rates of 
linear change of emotional functioning. Specifically, patients with higher pre-surgery level 
reported a slower increase of emotional functioning over time (B = -0.02; S.E. = 0.01; p < 
.01). 
Cognitive Functioning 
The best fit of Model 2 attested that there were significant between-subject variations in the 
initial level of emotional functioning and linear trajectories over time. Model 4 with UN 
covariance structure showed the best fit. At t1, cognitive functioning was 88.28 (S.E. = 1.51 
p < .001) and did not linearly increase over time (B = -0.34; S.E. = 0.19; n.s.). Patients with 
higher pre-surgery cognitive functioning level showed higher level at t1 (B = 0.50; S.E. = 
0.06; p < .001). Any of the sociodemographic or clinical variables influenced linear rate of 
change over time. 
Social Functioning 
The best fit of Model 2 attested that there were significant between-subject variations in the 
initial level of social functioning and linear trajectories over time. Model 5 with CS 
covariance structure showed the best fit. Social functioning at t1 was 82.49 (S.E. = 2.01; p 
< .001) and increased linearly over time (B = 0.74; S.E. = 0.22; p < .01). Patients with higher 
pre-surgery social functioning level showed higher level of social functioning at t1 (B = 
0.35; S.E. = 0.09; p < .001). Any of the sociodemographic or clinical variables influenced 
the linear rate of change of social functioning over time. 
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Fatigue 
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of fatigue, and linear and quadratic trajectories over time. Model 5 with CS 
covariance structure showed the best fit. A t1, the level of fatigue was 33.08 (S.E. = 2.22; p 
< .001), decreased linearly (B = -2.56; S.E. = 0.73; p < .01) but decelerated over time (B = 
0.15; S.E. = 0.07; p < .05). Patients with higher level of pre-surgery fatigue (B = 0.52; S.E. 
= 0.08; p < .001) and with perioperative complications (B = 8.01; S.E. = 3.35; p < .05) 
showed higher level of fatigue at t1. The experiencing of perioperative complications 
moderated the quadratic rate of growth of fatigue over time. Specifically, as shown in Figure 
10E, patients with perioperative complications, compared to patients without complications, 
reported a higher deceleration of decreasing rate of fatigue over time (B = 0.22; S.E. = 0.10; 
p < .05). 
Nausea and Vomiting 
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of nausea and vomiting and linear and quadratic trajectories over time. Model 4 
with UN covariance structure showed the best fit. After the inclusion of predictors, the level 
of nausea and vomiting at t1 was 8.938 (S.E. = 1.47; p < .001) and decreased linearly over 
time (B = -1.18; S.E. = 0.41; p < .01). Any of the sociodemographic or clinical variables 
influenced initial status of nausea and vomiting, neither linear and quadratic rate of change 
of fatigue over time. 
Pain 
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of pain and linear and quadratic trajectories over time. Model 4 with UN 
covariance structure showed the best fit. Pain at t1 was 23.60 (S.E. = 2.39; p < .001) and 
decreased linearly over time (B = -1.58; S.E. = 0.79; p < .05). Patients with higher pre-
surgery pain showed higher level of this QoL dimension at t1 (B=0.47; S.E.=0.11; p<.001).  
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Dyspnoea 
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of dyspnoea, and linear and quadratic trajectories over time. Model 5 with CS 
covariance structure showed the best fit. A t1, the level of dyspnea was 29.95 (S.E. = 2.37; 
p < .001) but it did not increase linearly (B = -0.77; S.E. = 2.37; n.s.) neither accelerated 
over time (B = -0.77; S.E. = 0.98; n.s.). Patients with higher level of pre-surgery dyspnea (B 
= 0.42; S.E. = 0.09; p < .001) and with perioperative complications (B = 9.41; S.E. = 3.59; 
p < .01) showed higher level of this QoL dimension at t1. The experiencing of perioperative 
complications moderated rates of both linear and quadratic change of dyspnoea. Specifically, 
as shown in Figure 10F, patients with perioperative complications, compared to patients 
without complications, reported a steeper decrease (B = -5.06; S.E. = 1.47; p < .01) but a 
faster deceleration of decreasing effect over time (B = .37; S.E. = 0.13; p < .01). 
Insomnia 
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of insomnia, and linear and quadratic trajectories over time. Model 6 with AR1 
covariance structure showed the best fit. As shown, the initial level of insomnia at t1 was 
28.11 (S.E. = 2.76; p < .001), decreased linearly (B = -3.73; S.E. = 0.93; p < .001) and 
decelerated over time (B = 0.24; S.E. = 0.08; p < .01). Patients with higher level of pre-
surgery insomnia showed higher level at t1 (B = 0.28; S.E. = 0.08; p < .001). Type of surgery 
moderated rates of both linear and quadratic change. Specifically, as shown in Figure 10G, 
patients undergoing robot-assisted surgery, compared to patients undergoing traditional 
surgery, reported a slower linear change (B =3.37; S.E. = 1.38; p < .05) but a slower 
deceleration of decreasing effect over time (B = -0.24; S.E. = 0.12; p < .05). 
Appetite Loss 
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of appetite loss, and linear and quadratic trajectories over time. Model 4 with 
UN covariance structure showed the best fit. Appetite loss at t1 was 26.63 (S.E. = 3.07; p < 
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.001), decreased linearly (B = -4.39; S.E. = 0.88; p < .001) and decelerated over time (B = 
0.24; S.E. = 0.08; p < .01). Patients undergoing robot-assisted surgery showed lower level 
of appetite loss at t1 (B = 12.17; S.E. = 4.56; p < .01). Moreover, type of surgery moderated 
rates of linear change of appetite loss over time. Specifically, as shown in Figure 10H, 
patients undergoing robot-assisted surgery, compared to patients undergoing traditional 
surgery, reported a slower linear decrease over time (B =3.01; S.E. = 1.31; p < .05). 
Constipation 
The best fit of Model 3 attested that there were significant between-subject variations in the 
initial level of constipation, and linear and quadratic trajectories over time. Model 4 with 
UN covariance structure showed the best fit. At t1, the initial level of constipation was 27.73 
(S.E. = 3.15; p < .001) and it decreased linearly over time (B = -2.89; S.E. = 0.97; p < .01). 
Patients with higher level of pre-surgery constipation showed higher subsequent level at t1 
(B = 0.56; S.E. = 0.09; p < .001). As shown in Figure 10I, the decreasing effect was faster 
for patients with higher level of pre-surgery constipation (B = -0.08; S.E. = 0.03; p < .01) 
but they showed less acceleration of decreasing effect over time (B = 0.01; S.E. = 0.00; p < 
.01). 
Diarrhea 
The best fit of Model 2 attested that there were significant between-subject variations in the 
initial level of diarrhea and linear trajectories over time. Model 4 with UN covariance 
structure showed the best fit. Diarrhea t1 was 6.73 (S.E. = 1.57; p < .001) but, after the 
inclusion of sociodemographic and clinical predictors, it did not linearly change over time 
(B = -0.11; S.E. = 0.24; n.s.). Patients with higher level of pre-surgery diarrhea showed 
higher level at t1 (B = 0.37; S.E. = 0.08; p < .001) and reported a faster decrease over time 
(B = -0.02; S.E. = 0.01; p < 0.5). 
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Financial Difficulties 
The best fit of Model 2 attested that there were significant between-subject variations in the 
initial level of financial difficulties and linear trajectories over time. Model 4 with UN 
covariance structure showed the best fit. At t1, financial difficulties score was 12.57 (S.E. = 
2.03; p < .001) but, after the inclusion of sociodemographic and clinical predictors, it did not 
linearly change over time (B = -0.04; S.E. = 0.25; n.s.). Patients with higher level of pre-
surgery financial difficulties (B = 0.42; S.E. = 0.06; p < .001) and younger patients (B = -
0.40; S.E. = 0.18; p < .05) reported higher level at t1. Moreover, patients with perioperative 
complications reported a faster increase of financial difficulties over time than patients 
without this kind of difficulties (B = 0.88; S.E. = 0.37; p < .05). 
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Figure 10: Longitudinal trends of QOL domains 
2.6.3 Discussion 
The present study identified one-year trends of patients’ QoL after pulmonary lobectomy for 
NSCLC and investigated whether clinical and sociodemographic variables may predict these 
trends. The individual change over time of the fifteen dimensions of the EORTC QLQ-C30 
and the effects of pre-surgery scores of QoL dimensions, type of surgery, perioperative 
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complications, and age on patients’ QoL after surgery were studied with the individual 
growth curve (IGCs) models.  
According to other previous studies[177], our results showed that patients had a good 
recovery after lobectomy. This is attested by an overall decrease of symptoms and an 
increase of health and functioning over time. However, levels of QoL at pre-surgery, type of 
surgery, perioperative complications, and patient’s age generally affected the post-surgery 
initial status of QoL as well as its linear and quadratic trends over time. This overall recovery 
in QoL is quite clear by looking at the results concerning the GHS. Specifically, patients’ 
health increased linearly over time. Pre-surgery GHS significantly affected its trend after 
lobectomy: lung cancer patients with high levels of pre-surgery GHS had better score at t1 
and better one-year recovery, even if their beneficial trend tended to slow down over time. 
Also, patients experiencing perioperative complications, compared with people with no 
complications, reported a greater deceleration of the recovery rate over time suggesting that 
this kind of patients are likely to experience a late relapse of global health.  
Referring to the European reference values for the quality of life questionnaire EORTC 
QLQ-C30 (2008)[178], one month after surgery (t1) patients globally reported high physical, 
role, emotional, cognitive and social functioning score rates, varying from 71.85 (role 
function) to 88.28 (cognitive function). Except for cognitive functioning (presenting high 
levels at all time periods), all the other functioning subscales linearly increased over time, 
showing a fast and good recovery after surgery. Only the recovery trend of physical and role 
functioning significantly decelerated over time: the linear improvement of both functions 
was faster in the first months after surgery and tended to become slower as time went on. 
Emotional, cognitive, and social subscales constantly increased over time indicating that 
patients are likely to have a good psychosocial recovery after surgery. A recent systematic 
review (2015) on QoL after lung cancer resection, showed physical functioning is the most 
affected dimension in patients with NSCLC, but all the EORTC QLQ-C30 subscales 
generally recover in 3-12 months after surgery[177].  
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Pre-surgery levels significantly impacted all functioning subscales at t1: patients with high 
levels of physical, role, emotional, cognitive, and social functions before surgery showed 
higher levels even one month after surgery. Moreover, patients with higher pre-surgery 
emotional functioning had a slower improvement of this QoL over time. Among the other 
aspects that may affect patients’ functions, type of surgery significantly impacted only on 
the linear and quadratic trend of physical functioning over time. Specifically, compared to 
patients undergoing robot-assisted surgery, people undergoing traditional surgery displayed 
a faster linear improvement in physical functioning after lobectomy, but this recovery 
remained less stable over time for patients undergoing traditional surgery. Balduyck et al. 
(2007)[179], analyzing patients undergoing traditional or robotic-assisted surgery, 
demonstrated that patients undergoing traditional lobectomy had worse effects on physical 
functioning and pain over one-year. Our results attested that patients’ functioning may be 
affected also by perioperative complications as well. Specifically, lung cancer patients with 
perioperative complications had lower scores in physical and role functions thirty days after 
surgery but a faster recovery from role functioning impairment. However, the speed of 
recovery from emotional problems tended to slow down more at later time (or become even 
worse) for patients experiencing complications.  
The symptom subscales trends were also investigated. Patients’ reported symptoms at t1 
were in line with the reference scores values[178] of lung cancer. Only dyspnoea and 
constipation symptoms were lower than their reference score means: 30 days after surgery 
patients reported dyspnoea of 29.95 and constipation of 27.73, whereas the average mean 
are 42.7 and 15.0, respectively. Since higher rates indicate worse symptoms, lung cancer 
patients undergoing lobectomy in our study had fewer problems of dyspnoea and more 
constipation than expected. This could be explained by the continuous use of post-operative 
pain killers even after 30 days conditioning a better pulmonary function due to less pain but 
increasing constipation. The one-year trend linearly decreased for fatigue, pain, insomnia, 
appetite loss, and constipation, suggesting a recovery from symptoms over time. However, 
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the speed of recovery gradually slowed down for fatigue and appetite loss as time from 
surgery went on, prolonging patients’ tiredness and inappetence.  
Pre-surgery levels significantly impacted fatigue, pain, dyspnea, insomnia, constipation, 
diarrhea, and financial difficulties at t1: patients with high levels of these symptoms before 
surgery showed higher problems even at t1. Moreover, patients with higher pre-surgery 
levels of constipation and diarrhea had a faster decrease in these symptoms over time, but 
the first one showed a slower recovery in the last months of the one-year trend. The type of 
surgery significantly impacted insomnia and appetite loss rates at t1 and over time: patients 
undergoing robot-assisted surgery had low scores at t1 but a slower improvement after 
lobectomy in these symptoms than patients undergoing traditional surgery. This slow 
improvement is probably due to the favorable initial condition: patients undergoing robot-
assisted surgery had fewer symptoms at t1, and they may not further improve over time since 
they already had high scores thirty days after surgery. However, the significant negative 
quadratic change of insomnia showed that it remained more stable over time for patients 
undergoing robot-assisted lobectomy, suggesting that patients undergoing traditional 
surgery were more likely to experience a worsening of sleep problems at later time. 
Perioperative complications significantly affected the t1 scores of dyspnoea and fatigue: lung 
cancer patients with perioperative complications had higher levels of dyspnoea and fatigue 
thirty days after surgery. Moreover, complications affected the recovery of dyspnoea and 
financial difficulties over time: patients with no complications had a faster increase of 
dyspnoea symptom and a slower increase in financial difficulties and spent less money. 
Finally, the quadratic change of dyspnoea and fatigue were impacted by perioperative 
complications, showing a greater slowdown of the recovery for patients with complications. 
Age significantly impacted only on financial difficulties: younger patients had greater 
financial problems thirty days after surgery than older people. 
The obtained results identify different one-year trends of lung cancer patients’ QoL after 
lobectomy. All sub-dimensions had a specific recovery: functioning subscales improved 
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over time, while most of the symptoms became less severe over the care process. 
Perioperative complications, type of surgery, pre-surgery status and age significantly 
affected these trends, thus becoming predictors of patients’ QoL. In fact, in this paper it was 
often demonstrated that pre-surgery QoL rates often predicted post-surgery status and trends, 
while the type of surgery, age, and perioperative complications often affect patients’ well-
being and recovery. Therefore, the measurement of pre- and post-surgery QoL and its 
clinical and sociodemographic covariables would be necessary to better investigate patients’ 
care process and implement personalized medicine in lung cancer hospital divisions. A 
patient-centered approach would be important to develop preventive programs, analyze both 
psychological and medical outcomes that could affect patient’s recovery, and improve 
patient empowerment[180,181]. 
Limitations 
Current results may be considered in light of some main limitations. Specifically, because 
of sample size, it was not possible to identify different typologies of patients following 
different longitudinal trajectories of QoL: 176 patients with lung cancer were not enough to 
distinguish different trend of recovery. This study shows the average one-year trend, but it 
did not identify different classes of patients with different recovery after surgery. Future 
studies should be conducted on a larger sample in order to perform other statistical analyses 
with a typological approach that can better describe patients’ recovery. It would be also 
important to collect data on the effects of other psychological aspects that may significantly 
impact the trend of patients’ QoL. For example, illness perception, resilience, coping, and 
self-efficacy are only some of the important aspects that should be measured over the care 
cycle and may modify patients’ recovery after surgery[182–184]. Future studies are needed 
to better identify covariables that may impact on lung cancer patients’ QoL and identify 
different trajectories of patients’ recovery[185]. Moreover, measured outcomes were 
collected up to only one year after surgery: it would be important to extend the follow-ups, 
in order to better analyze patient’s recovery of functions, which mostly lasts more than one 
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year after treatments. Lastly, since QoL is strictly associated with survivorship rates, it would 
be useful to conduct another project studying which QoL sub-dimensions may interact or 
affect patients’ survivorship[162].  
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3. Conclusions 
The VBHC paradigm aims at improving the health care process, collecting data from a 
psychological, clinical and economic perspective and improving the quality of care. This 
paradigm has been implemented in different health care organizations, even if combining 
countries’ current health care systems and the VBHC model is still a challenge. In Italy, only 
two health care organizations are currently applying some aspects of the VBHC model. The 
European Institute of Oncology applied the VBHC framework to different medical divisions, 
implementing the VBM project. Clinical, psychological and economic data have been 
collected in prostate and lung cancer patients for two years. The VBM project aims at 
analysing principal and interaction effects between outcomes and costs investigating the 
associations among psychological, medical and economic aspects of patient’s process of 
care, and studying if the psychological status may impact on costs, rehabilitation, drug 
consumption and medical examinations. The Psychoncology division focused on patients’ 
well-being in order to identify trend of clinical and psychological status over time and predict 
this change with sociodemographic or medical variables. A person-oriented approach was 
used to analyze patients’ recovery: one-year QoL trends in early stage of lung and prostate 
cancer patients undergoing surgery were identified, along with the sociodemographic and 
clinical factors that may impact and affect these trends. Patients’ recovery after surgery was 
characterized by an overall decrease of symptoms and an increase of health and functioning 
over time. In lung cancer, levels of QoL at pre-surgery, type of surgery, perioperative 
complications, and patient’s age generally affected post-surgery initial status of QoL as well 
as its linear and quadratic trends over time. On the contrary, due to a larger sample, different 
categories of prostate cancer patients characterized by different trend of clinical and 
psychological status over time were also identified: five and three classes were found for 
urinary incontinence and sexual dysfunction subscales, respectively. The membership to one 
of the identified classes may be affected by age, pre-surgical condition and BMI. However, 
all the predictors analysed so far were clinical or sociodemographic variables; psychological 
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outcomes should be included to better understand the differences among patients’ 
trajectories. Finding different categories of patients at risk may be important to develop 
personalized medical pathways and predictive models in value-based health care. Through 
the collection of clinical outcomes and costs, a predictive model of patients’ recovery would 
be developed, allowing a more precise framework on patients’ care pathway. Predictive 
models would improve medical decision-making, the choice of treatment, and patients’ 
awareness about their care process: in this way, potential risks, QoL, and expected outcomes 
would be more predictable and better manageable. Even the patient would be more 
empowered, thus becoming an active decision-maker[106]. Starting from data collected on 
prostate and lung cancer patients, the second phase of the VBM project will be to implement 
and validate a personalized model able to predict the patient’s care process. According to the 
sociodemographic and clinical characteristics, every patient will receive a personalised 
predictive model of his/her functional and psychological recovery after surgery. At the first 
medical consultation in the Urology Division at the IEO, prostate cancer patients candidate 
for RARP will receive a personalized predictive model that allow both patients and 
physicians to gather more information about treatments’ risks and expected outcomes over 
time. To understand the effects of this innovative form of communication of clinical results, 
a qualitative analysis will be carried out by a psychologist who will verify the degree of 
patients’ awareness about their clinical-functional risk profile. The semi-structured interview 
will be conducted after the creation and explanation of the “profile” and before the patient 
will undergo surgery; emotional and cognitive aspects related to the diagnosis and the 
expected recovery will be also investigated. 
Another future direction would be to investigate patients’ QoL and trajectories of recovery 
by differentiating for type of cancer. Until now, the process of care for single type of cancer 
has been analysed, but they have not yet been compared. Every cancer is characterized by 
specific drug consumption and side effects, different time for recovery, and costs; comparing 
17 
 
the trajectories among patients with lung and prostate cancer would allow to understand 
which factors may influence both processes of care. 
Despite all the advancements in predicting patients’ trajectories of recovery, the 
psychological dimension needs to be further investigated. Until now, QoL was the only 
measured psychological outcome in prostate and lung cancer patients, but several aspects of 
the predictive trajectories of patients’ recovery were still unexplained. The obtained results 
emphasised the need to add other variables that may significantly affect patients’ care 
pathway. Next studies referring to the VBM project will improve these aspects.  
For this reason, the VBM project that would focus on breast cancer patients will implement 
specific modifications to the related research protocol: psychological variables that may 
affect the overall status of the patient will be included. Thereby, to further investigate which 
factors may moderate or mediate the psychological dimension of cancer patients, other 
psychological variables would be included in the VBM Breast Cancer research protocol.  
3.1 The VBM project on breast cancer patients: a new challenge. 
According to these research trajectories a new research protocol has been developed on 
breast cancer patients at European Institute of Oncology. The Value-Based Project in the 
Breast Unit (VBM-Breast Protocol) aims to implement VBHC model along the disease 
trajectory in breast cancer patients. In details, it is a concrete attempt to achieve a depth 
integration, validation and dissemination of the VBHC model in clinical practice for cancer 
disease in the Italian context. The VBM-Breast Protocol was developed after the conclusion 
of prostate and lung cancer studies and it has been nested in the same theoretical background.  
The high incidence of breast cancer (more than 2.1 million women in the world[41]) and  the 
clinical, psycho-social and economic  implications related to it, have stressed the importance 
of an integrative and comprehensive model able to explain the complexity of this condition.  
Furthermore, the studies on prostate and lung cancer patients showed that QoL deeply affects 
patients’ recovery after surgery, underlining the importance of psychological aspects in 
cancer care. These results suggested the crucial role of psycho-social factors in defining 
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health status of cancer patients. More in details, evidence have reported the importance of 
specific psychological mechanisms such as : resilience, self-efficacy, optimism, and illness 
perception[186–189]. These variables may scale up the assessment of the QoL. For example, 
innovative relations have been found for resilience.  In the context of cancer, resilience has 
been recently defined as dynamic “individual’s protective attributes and/or personal 
characteristics, which are thought to be modifiable and to promote successful adaptation to 
cancer, including, among others, meaning and purpose in life, sense of coherence, optimism, 
positive emotions, self-esteem, self-efficacy, cognitive flexibility, coping, social support, 
and spirituality”[190]. Breast cancer women with low levels of resilience have a worse 
perception of their body image and more severe symptoms, thus impacting different HRQoL 
aspects[188]. Other studies showed that self-efficacy and optimism may affect patients’ 
abilities to cope with cancer and improve psychological well-being: high levels of self-
efficacy and dispositional optimism are associated with better QoL among breast cancer 
patients[191,192]. Lastly, illness perception is defined as “patients’ cognitive, feelings, and 
emotions about symptoms they experience and their disease in general”; several scientific 
studies showed its relationship with breast cancer patients’ QoL[193]. Since illness 
perception showed an high association with low levels of HRQoL, it would be important to 
better investigate its role as a possible mediator/moderator on QoL[187].  
Within the VBM - Breast project these psychological variables were included in order to not 
only identify trend of patients’ recovery over time variables, but also to analyze which 
psychological factors may mediate or moderate QoL outcomes over the care cycle. In order 
to disseminate the principles of VBHC model, the VBM-Breast project will be designed as 
a multicentre prospective longitudinal study, thus involving different Italian Hospitals. The 
Italian Hospital involved are the European Institute of Oncology, the Istituto Nazionale dei 
Tumori IRCCS, the ASST Papa Giovanni XXIII (Bergamo), the ASST dei 7 Laghi (Varese), 
the Fondazione Policlinico S. Matteo IRCCS (Pavia), and the ASST di Cremona. Based on 
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the number of patients undergoing breast cancer surgery per year, different sample size will 
be calculated. Table 16 shows the expected number of patients to be enrolled. 
Table 16. Expected number of patients to be enrolled at each healthcare organizations 
Hospital Expected number of patients 
European Institute of Oncology IRCCS 900 
Istituto Nazionale dei Tumori IRCCS 300 
ASST Papa Giovanni XXIII 150 
ASST dei 7 Laghi 120 
Fondazione Policlinico S. Matteo IRCCS 80 
ASST di Cremona 80 
 
For all the healthcare institutions, only patients 1) older than 18 years, 2) with primary breast 
cancer, and 3) undergoing mastectomy or quadrantectomy with or without reconstruction 
would be enrolled. 
According to patients’ follow-ups, data will be collected at different time points – at pre-
surgery (t0), 1 (t1), 6 (t2), 12 (t3), and 24 (t4) months after surgery – through specific 
standardized questionnaires measuring the above-mentioned psychological variables. 
The EORTC QLQ-C30 and the EORTC QLQ-BR-23, two self-report questionnaires 
composed of 30 and 23 items, respectively, will be used to measure QoL in breast cancer 
patients. The EORTC QLQ-C30 has already been described in the lung cancer section; on 
the contrary, the specific section BR-23 is used to assess specific symptoms related to the 
breast cancer condition. In fact, it is composed by five sub-scales assessing body image, 
sexual functioning, sexual enjoyment, future perspective, treatments’ side effects, breast 
symptoms, arm symptoms and upset by hair loss[116,122,194]. 
Resilience will be measured through the Resilience Scale for Adult (RSA), a 33-items 
questionnaire with different sub-scales collecting inter- and intra-personal protective factors 
that may influence the patient’s adjustment. More specifically, intra-personal subscales 
20 
 
investigate self-perception, planned future, social competence, and structured style. On the 
contrary, inter-personal subscales assess family cohesion and social resources[195,196]. 
Self-efficacy is a context-specific variable that will be assessed through the brief version of 
the Cancer Behavior Inventory (CBI-B), a 14 items survey with a 9-points Likert scale. The 
questionnaire investigated the ability to maintain independence and positive attitude, seeking 
and understanding medical information, coping and stress management, and the emotion 
regulation[197,198]. Dispositional optimism is a relatively stable psychological resource 
[199] assessed by the Life Orientation Test-Revised (LOT-R), a self-report questionnaire of 
10 items with a 5-points Likert scale[135,200]. Finally, illness perception will be measured 
with the Brief Illness Perception Questionnaire (BIP-Q), a 9-items self-report scale that 
investigates cognitive and emotional representations of illness, and comprehension of 
illness[201]. 
A trained psychologist will meet patients at pre-surgery, giving them the inform consent and 
collecting psychological variables through the standardized questionnaires. During the 
follow-ups, data will be collected through a specific e-health platform called REDCup. 
Patients with low psychological well-being will be then contacted and their needs will be 
investigated. 
Concluding, the VBM-Breast Protocol is a key opportunity and a pivotal challenge to try to 
confirm the results obtained in Study 1b on prostate cancer and Study 2b on lung cancer and 
to integrate the VBHC model in clinical practice for cancer care using a patient centered 
approach. This approach will permit to identify all psychological, social and economic 
unmet need of the cancer patients and try to respond them. 
The implementation of this approach will improve decision-making in clinicians and patients 
pushing them to achieve a shared decision about treatments. Consequently, it guarantees the 
opportunity to better involve the cancer patients in their disease management, empowering 
them. 
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Appendix 
A1. Search strategy for the review on Italian hospitals applying the VBHC to medical 
practice 
 
 
Search Engine: Search String: Hits Relevanta Includedb 
Pubmed ((("italy")[Title/Abstract] OR "italian"[Title/Abstract])) AND 
(("vbhc")[Title/Abstract] OR "value based 
healthcare"[Title/Abstract]) 
7 1 1 
Scopus (TITLE-ABS-KEY ( VBHC  OR  “value-based healthcare”) )  
AND  ( TITLE-ABS-KEY ( Italy  OR  Italian) )   
2 1 1  
Web of Science TS = ("VBHC" OR "value-based healthcare") AND TS=("Italy" 
OR "Italian") 
1 1 1  
Cochane Library vbhc OR "value-based heathcare") AND (Italy OR Italian) in Title 
Abstract Keyword 
0 0 0 
Embase (vbhc OR 'value-based healthcare') AND ('italy'/exp OR italy OR 
'italian'/exp OR italian) 
14 1 1  
Medline Ovid  (("VBHC" or "value-based healthcare") and (Italy or Italian)).af. 4 0 0 
Subtotal 
 
28 4 4 
Duplicates 
   
3 
Total 
 
28 4 1 
a Relevant: number of relevant articles based on title, abstract, and keywords 
b Included: number of included articles based on full article 
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A2. The Expanded Prostate Cancer Index Composite – Short Form (EPIC-26) 
 
  
 
 
 
 
 
 
 
 
 
This questionnaire is designed to measure Quality of Life issues in patients with Prostate cancer. To help us get the most 
accurate measurement, it is important that you answer all questions honestly and completely. 
 
Remember, as with all medical records, information contained within this survey will remain strictly confidential. 
 
 
 
 
 
 
 
Today's Date (please enter date when survey completed):  Month  Day  Year   
 
 
Name (optional):     
 
 
Date of Birth (optional): Month  Day  Year   
EPIC-26 
The Expanded Prostate Cancer Index Composite 
Short Form 
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A3. The European Organization for Research and Treatment of Cancer (EORTC) 
Quality of Life Questionnaire-Core 30 (QLQ-C30) 
EORTC QLQ-C30 (version 3) 
We are interested in some things about you and your health. Please answer all of the questions 
yourself by circling the number that best applies to you. There are no "right" or "wrong" answers. 
The information that you provide will remain strictly confidential. 
 
 
  
Please fill in your initials:   
Your birthdate (Day, Month, Year):  
Today's date (Day, Month, Year): 31  
 
 
1. Do you have any trouble doing strenuous activities, 
Not 
at 
All 
A 
Lit
tle 
Qui
te a 
Bit 
Ve
ry 
Mu
ch 
like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
2. Do you have any trouble taking a long walk? 1 2 3 4 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4 
5. Do you need help with eating, dressing, 
washing yourself or using the toilet? 
 
1 
 
2 
 
3 
 
4 
During the past week: 
 
Not 
at 
 
A 
 
Qu
ite 
 
Ver
y 
 All Lit
tle 
a 
Bit 
Mu
ch 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
7. Were you limited in pursuing your hobbies or 
other leisure time activities? 
 
1 
 
2 
 
3 
 
4 
8. Were you short of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 1 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? 1 2 3 4 
15. Have you vomited? 1 2 3 4 
16. Have you been constipated? 1 2 3 4 
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During the past week: 
 
17. Have you had diarrhea? 
No
t 
at 
All 
 
1 
A 
Litt
le 
 
2 
Qui
te a 
Bit 
 
3 
Ver
y 
Mu
ch 
 
4 
18. Were you tired? 1 2 3 4 
19. Did pain interfere with your daily activities? 1 2 3 4 
20. Have you had difficulty in 
concentrating on things, like reading 
a newspaper or watching television? 
 
1 
 
2 
 
3 
 
4 
21. Did you feel tense? 1 2 3 4 
22. Did you worry? 1 2 3 4 
23. Did you feel irritable? 1 2 3 4 
24. Did you feel depressed? 1 2 3 4 
25. Have you had difficulty remembering things? 1 2 3 4 
26. Has your physical condition or 
medical treatment interfered with 
your family life? 
 
1 
 
2 
 
3 
 
4 
27. Has your physical condition or 
medical treatment interfered with 
your social activities? 
 
1 
 
2 
 
3 
 
4 
28. Has your physical condition or 
medical treatment caused you 
financial difficulties? 
 
1 
 
2 
 
3 
 
4 
 
  
 
 
 
 
 
 
 
  
For the  following  questions  please  circle  the  number  between   1  and  7  that   
best applies to you 
29. How would you rate your overall health during the past week? 
 
1 2 3 4 5 6 7 
 
Very poor Excellent 
 
 
30. How would you rate your overall quality of life during the past week? 
 
1 2 3 4 5 6 7 
 
Very poor Excellent 
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